var title_f16_6_16480="Brow anterior presentation";
var content_f16_6_16480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brow anterior presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dystocia Caused by Abnormalities in Presentation, Position, or Development of the Fetus. In: Williams Obstetrics, 16th Edition, Pritchard, JA, MacDonald, PC (Eds), Appleton-Century-Crofts, New York 1980. p.812. Copyright &copy; 1980 McGraw Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16480=[""].join("\n");
var outline_f16_6_16480=null;
var title_f16_6_16481="Framycetin: International drug information";
var content_f16_6_16481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Framycetin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5027600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Soframycin (CA, NZ, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F5027601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Framycetin Sulfate;",
"     </li>",
"     <li>",
"      Framycetin Sulphate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F5027602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Otic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F5027603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conjunctivitis, blepharitis, styes, corneal abrasions, and burns; prophylactically following foreign body removal from the eye; corneal ulcers; otitis externa",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F5027605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Drops: Initial: 1-2 drops into affected eye(s) every 1-2 hours for 2-3 days, decreasing to 2-3 drops 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ointment: 3 times/day into affected eye(s), or at bedtime, if drops are used during the day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Drops: 2-3 drops or a saturated wick into external auditory meatus 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ointment: Apply 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5027606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment, ophthalmic/otic: 5 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic/otic drops: 8 mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10475 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16481=[""].join("\n");
var outline_f16_6_16481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027600\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027601\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027602\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027603\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027605\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821071\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027606\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10475\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10475|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_6_16482="STAR system";
var content_f16_6_16482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    The STAR (stereotactic alignment radiosurgery) system at the MGH northeast proton therapy center (MGH-NPTC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An isocentric patient positioning device designed to rotate the patient around a fixed proton beam line. The unit has five degrees of freedom, three linear and two rotations. Using these axes of movement, the patient is positioned such that the target lesion is at the center of the beam isocenter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16482=[""].join("\n");
var outline_f16_6_16482=null;
var title_f16_6_16483="EUS celiac ganglion inject";
var content_f16_6_16483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    EUS celiac ganglion inject",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Initial pre-injection appearance (A) of a celiac ganglion as compared to that following injection (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16483=[""].join("\n");
var outline_f16_6_16483=null;
var title_f16_6_16484="Ofloxacin (otic): Patient drug information";
var content_f16_6_16484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ofloxacin (otic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=see_link\">",
"     see \"Ofloxacin (otic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/42/20131?source=see_link\">",
"     see \"Ofloxacin (otic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ofloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Earache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in back of the ankle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12271 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-0D5B978519-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16484=[""].join("\n");
var outline_f16_6_16484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024486\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024485\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024490\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024491\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024493\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024488\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024489\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024494\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024495\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=related_link\">",
"      Ofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30020?source=related_link\">",
"      Ofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21363?source=related_link\">",
"      Ofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=related_link\">",
"      Ofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/42/20131?source=related_link\">",
"      Ofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=related_link\">",
"      Ofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=related_link\">",
"      Ofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/28/34246?source=related_link\">",
"      Ofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_6_16485="Lomitapide: Patient drug information";
var content_f16_6_16485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lomitapide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"     see \"Lomitapide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16150139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Juxtapid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15962329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems in some patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4100646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You can only get this drug through the Juxtapid REMS Program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15962331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15962330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4100648",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lomitapide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15962335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel disease such as Crohn's disease or ulcerative colitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2770240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15962336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3572837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15962337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15962333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4100963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at least 2 hours after the evening meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4100964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take with food. It may cause an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, open, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15962334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15962338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15962339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87671 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16485=[""].join("\n");
var outline_f16_6_16485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16150139\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962329\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962331\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962330\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962335\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962336\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962337\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962333\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962334\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962338\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962339\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=related_link\">",
"      Lomitapide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_6_16486="Brentuximab vedotin: Drug information";
var content_f16_6_16486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brentuximab vedotin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/23/3445?source=see_link\">",
"    see \"Brentuximab vedotin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13713190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13204259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adcetris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16369259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adcetris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13190981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13203262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For patients weighing &gt;100 kg, dose should be calculated using a weight of 100 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hodgkin lymphoma, refractory:",
"     </b>",
"     I.V.: 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until disease progression, unacceptable toxicities, or a maximum of 16 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Systemic anaplastic large cell lymphoma (sALCL), refractory:",
"     </b>",
"     I.V.: 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until disease progression, unacceptable toxicities, or a maximum of 16 cycles",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13203263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13203265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; active drug (MMAE) pharmacokinetics have not been determined in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13203264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; active drug (MMAE) pharmacokinetics have not been determined in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F13203279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Grade 3 or 4 neutropenia:",
"     </i>",
"     Withhold treatment until resolves to baseline or &le;grade 2, consider growth factor support in subsequent cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Recurrent grade 4 neutropenia (despite the use of growth factor support):",
"     </i>",
"     Consider reducing the dose to 1.2 mg/kg or discontinuing treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Grade 3 or 4 thrombocytopenia (Canadian labeling):",
"     </i>",
"     Monitor closely; dose delays or platelet transfusions may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nonhematologic toxicities:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Anaphylaxis:",
"     </i>",
"     Discontinue immediately and permanently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Infusion reaction:",
"     </i>",
"     Interrupt infusion and administer appropriate medical intervention. Premedicate subsequent infusions with acetaminophen, an antihistamine, and/or a corticosteroid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Peripheral neuropathy, new or worsening grade 2 or 3:",
"     </i>",
"     Withhold treatment until improves or returns to grade 1 or baseline; then resume with dose reduced to 1.2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Peripheral neuropathy, grade 4:",
"     </i>",
"     Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Progressive multifocal leukoencephalopathy (PML):",
"     </i>",
"     Withhold treatment with new-onset symptoms suggestive of PML; discontinue if PML diagnosis confirmed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Stevens-Johnson syndrome:",
"     </i>",
"     Discontinue and administer appropriate medical intervention",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13204260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adcetris&trade;: 50 mg [contains polysorbate 80; derived from or manufactured using hamster or mouse protein]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13203233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13203282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 30 minutes. Do not administer as I.V. push or bolus; do not mix or infuse with other medications. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13203252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or lactated Ringer&rsquo;s; do not mix with or administer as an infusion with other products",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13190983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Hodgkin lymphoma after failure of at least 2 prior chemotherapy regimens (in patients ineligible for transplant) or after stem cell transplant failure; treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 prior chemotherapy regimen",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13190979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Brentuximab may be confused with bendamustine, bevacizumab, rituximab",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13203241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (4% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (41% to 49%), fever (29% to 38%), pain (7% to 28%), headache (16% to 19%), insomnia (14% to 16%), dizziness (11% to 16%), chills (12% to 13%), anxiety (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (27% to 31%), pruritus (17% to 19%), alopecia (13% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (38% to 42%), diarrhea (29% to 36%), abdominal pain (9% to 25%), vomiting (17% to 22%), constipation (16% to 19%), appetite decreased (11% to 16%), weight loss (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (54% to 55%; grade 4: 6% to 9%); anemia (33% to 52%; grade 4: &le;2%), thrombocytopenia (16% to 28%; grade 4: 2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Peripheral sensory neuropathy (52% to 53%; grade 3: 8% to 10%), arthralgia (9% to 19%), myalgia (16% to 17%), peripheral motor neuropathy (7% to 16%; grade 3: 3% to 4%), back pain (10% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (12% to 47%), cough (17% to 25%), dyspnea (13% to 19%), oropharyngeal pain (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infusion reactions (grades 1/2: 12%), night sweats (9% to 12%), lymphadenopathy (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Supraventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dry skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Limb pain, muscle spasms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Pyelonephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pneumonitis, pneumothorax, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibrentuximab antibody formation, septic shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, progressive multifocal leukoencephalopathy (PML), Stevens-Johnson syndrome, tachycardia, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13203237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     U.S. labeling: Concurrent use with bleomycin",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to brentuximab or any component of the formulation; concurrent use with bleomycin; patients who have or have history of progressive multifocal leukoencephalopathy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13203238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Neutropenia, thrombocytopenia and anemia may occur.  Neutropenia may be prolonged (&ge;1 week). Monitor blood counts. May require dose interruption, reduction or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion reactions: Infusion reactions, including anaphylaxis have been reported. Monitor during infusion. For anaphylaxis, immediately and permanently discontinue and administer appropriate medical intervention. For infusion-related reaction, interrupt infusion and administer appropriate medical intervention; premedicate for subsequent infusions (with acetaminophen, an antihistamine, and/or a corticosteroid).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral neuropathy: Peripheral neuropathy is common and is generally cumulative. Usually sensory neuropathy, although motor neuropathy has also been observed. Neuropathy completely resolved in nearly half of patients; almost one-third had partial improvement. Monitor for symptoms of neuropathy. Dose interruption, reduction or discontinuation may be recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Progressive multifocal leukoencephalopathy (PML):",
"     <b>",
"      [U.S. Boxed Warning]: Cases of PML and death due to JC virus infection have been reported.",
"     </b>",
"     Immunosuppression due to prior chemotherapy treatments or underlying disease may also contribute to PML development. New-onset signs/symptoms of central nervous system abnormalities (eg, changes in mood, memory, cognition, motor incoordination and/or weakness, speech and/or visual disturbances) should receive prompt evaluation with neurology consultation, brain MRI, and lumbar puncture or brain biopsy. Withhold treatment with new-onset symptoms suggestive of PML; discontinue if diagnosis of PML is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Stevens-Johnson syndrome: Stevens-Johnson syndrome has been observed. Discontinue and administer appropriate medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) may occur; risk of TLS is higher in patients with a high tumor burden or with rapid tumor proliferation. Monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: A component of brentuximab vedotin, the microtubule-disrupting agent MMAE is excreted hepatically; the impact of hepatic impairment on MMAE pharmacokinetics is undetermined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: A component of brentuximab vedotin, the microtubule-disrupting agent MMAE is excreted renally; the impact of renal impairment on MMAE pharmacokinetics is undetermined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Concurrent drug therapy issues:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleomycin: Due to the risk for pulmonary injury, concurrent use with bleomycin is contraindicated. In a study comparing brentuximab combined with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) to brentuximab combined with AVD (doxorubicin, vinblastine, and dacarbazine), the occurrence of pulmonary toxicity was 40% in the brentuximab/ABVD group compared to a literature-based frequency of &le;25% for other bleomycin-containing regimens. There were no cases of pulmonary toxicity documented with brentuximab in combination with AVD. Pulmonary symptoms/toxicities reported with brentuximab in combination with ABVD consisted of cough, dyspnea, and interstitial infiltration/inflammation; most patients responded to corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13225881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bleomycin: Brentuximab Vedotin may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13203234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13203235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryo-fetal toxicities and fetal malformations were noted in animal reproduction studies. Based on the mechanism of action, may cause fetal harm if administered to a pregnant woman.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13203639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13203236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if brentuximab vedotin is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Adcetris Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $5808.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13203286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential prior to each dose (more frequently if clinically indicated). Monitor for infusion reaction, tumor lysis syndrome, and for signs of neuropathy (hypoesthesia, hyperesthesia, paresthesia, discomfort, burning sensation, or neuropathic pain or weakness).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13203253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Brentuximab vedotin is an antibody drug conjugate (ADC) directed at CD30 consisting of 3 components: 1) a CD30-specific chimeric IgG1 antibody cAC10;  2) a microtubule-disrupting agent, monomethylauristatin E (MMAE); and 3) a protease cleavable dipeptide linker (which covalently conjugates MMAE to cAC10). The conjugate binds to cells which express CD30, and forms a complex which is internalized within the cell and releases MMAE. MMAE binds to the tubules and disrupts the cellular microtubule network, inducing cell cycle arrest (G2/M phase) and apoptosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13203255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : ADC: 6-10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: MMAE: Minimal, primarily via oxidation by CYP3A4/5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: ADC: ~4-6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ADC: At end of infusion; MMAE: ~1-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: MMAE: Feces (~72%, primarily unchanged); urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chen RW, Gopal AK, Smith SE, et al, &ldquo;Results From a Pivitol Phase II Study of Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):8031 [abstract 8031 from 2011 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pro B, Avandi R, Brice P, et al, &ldquo;Durable Remissions With Brentuximab Vedotin (SG-35): Updated Results of a Phase II Study in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15s):8032 [abstract 8032 from 2011 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Younes A, Bartlett NL, Leonard JP, et al, &ldquo;Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      2010, 363(19):1812-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/6/16486/abstract-text/21047225/pubmed\" id=\"21047225\" target=\"_blank\">",
"        21047225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Younes A, Connors JM, Park SI, et al, &ldquo;Frontline Therapy With Brentuximab Vedotin Combined With ABVD or AVD in Patients With Newly Diagnosed Advanced Stage Hodgkin Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):955  [abstract 955 from 2011 ASH Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16806 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16486=[""].join("\n");
var outline_f16_6_16486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13713190\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204259\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369259\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13190981\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203262\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203263\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203265\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203264\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203279\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204260\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203233\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203282\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203252\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13190983\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13190979\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203241\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203237\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203238\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298881\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13225881\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203234\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203235\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203639\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203236\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322915\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203286\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203253\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203255\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16806|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/23/3445?source=related_link\">",
"      Brentuximab vedotin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_6_16487="Strategies for improving the efficacy of clomiphene induction of ovulation";
var content_f16_6_16487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strategies for improving the efficacy of clomiphene induction of ovulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16487/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16487/contributors\">",
"     Mark D Hornstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16487/contributors\">",
"     William E Gibbons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16487/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16487/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16487/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/6/16487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate is the fertility medication most widely prescribed by gynecologists. Its use results in ovulation and pregnancy rates of 80 and 40 to 50 percent, respectively, when given at standard doses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/1\">",
"     1",
"    </a>",
"    ]. The United States Food and Drug Administration (FDA) has approved use of clomiphene at doses of 50 or 100 mg daily for five days per cycle.",
"   </p>",
"   <p>",
"    Women who ovulate but who do not conceive should not be considered \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate failures.\" In one series, 88 percent of women who ovulated with no other infertility factor conceived, while only 8 percent of those with concurrent infertility factors conceived. This observation highlights the importance of performing an evaluation of fertility factors in women who ovulate but do not conceive before moving to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current guidelines from a consensus group recommend that women who do not become pregnant with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    should be treated with gonadotropin injections (follicle stimulating hormone [FSH] or FSH and luteinizing hormone [LH]) or laparoscopic ovarian surgery to reduce androgen secretion by the ovary. However, it is worthwhile to review less complex, alternative approaches to treating these women before referring them for resource intensive interventions. Some of these strategies (eg, weight loss) can also be considered at the initial course of clomiphene therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=see_link\">",
"     \"Laparoscopic surgery for ovulation induction in polycystic ovary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strategies for fertility treatment in the 50 to 60 percent of women with ovulatory infertility who do not become pregnant when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    as a single agent will be reviewed here. An optimal sequence for these strategies has not been determined; the sequence described below reflects our typical approach to these patients. A general overview of ovulation induction with clomiphene citrate is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REVIEW THE CAUSE OF INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If pregnancy has not occurred after three cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    treatment, it is worthwhile to review the diagnostic studies that were completed by the infertile couple and consider further investigation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the semen analysis was abnormal, consultation with a fertility specialist is warranted. A markedly abnormal semen analysis may be best treated with IVF-ET or intracytoplasmic sperm injection (ICSI). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The female partner's serum FSH, thyroid stimulating hormone (TSH), prolactin, testosterone, and dehydroepiandrosterone sulfate (DHEA-S) concentrations should be reviewed, or ordered if they have not been obtained previously.",
"     </li>",
"     <li>",
"      If the FSH level is elevated, the ovarian oocyte pool may be depleted and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      is not likely to be effective. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"       \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"       \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased TSH or prolactin requires specific treatment for hypothyroidism and hyperprolactinemia, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"       \"Treatment of hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"       \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the testosterone or DHEA-S concentration is elevated, the source of androgen excess should be investigated so that appropriate therapy can be initiated. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Combination therapy with glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The age of the female partner is also an important determinant of fertility potential. Women over 37 years of age have a lower fertility potential, thus consideration of IVF-ET and other fertility technologies may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHO CLASSIFICATION OF ANOVULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classification categorizes women with anovulation into three major groups (WHO group I, WHO group II, and WHO group III) based upon gonadotropin levels.",
"   </p>",
"   <p>",
"    WHO group I refers to anovulatory women with low levels of endogenous gonadotropins and very low endogenous estrogen production. These women tend not to have withdrawal uterine bleeding after a progestin challenge, nor do they usually ovulate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    treatment. They may respond to pulsatile gonadotropin releasing hormone (GnRH) therapy or gonadotropin injections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some women in WHO group I are lean (body mass index [BMI] less than 20",
"    <span class=\"nowrap\">",
"     kg/m2);",
"    </span>",
"    weight",
"    <strong>",
"     gain",
"    </strong>",
"    in these women may be associated with spontaneous ovulation or improved responsiveness to ovulation induction agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WHO class III refers to hypergonadotropic hypoestrogenic anovulation, and accounts for 10 to 30 percent of cases of anovulation. The primary causes are primary ovarian insufficiency (premature ovarian failure; absence of ovarian follicles due to early menopause) or ovarian resistance (follicular form). These women may require gonadotropin therapy, IVF-ET, or oocyte donation; they usually do not respond to any therapy for anovulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The strategies described in this topic are for women with WHO II women and are not useful in WHO group I and group III women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OPTIONS FOR WOMEN WITH WHO TYPE II ANOVULATORY INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;WHO group II refers to women with relatively normal gonadotropin levels and evidence of significant endogenous estrogen production. Women in WHO group II usually have withdrawal uterine bleeding after a progestin challenge. The most common cause of ovulatory dysfunction in WHO group II patients is the polycystic ovary syndrome (PCOS). Several professional groups have proposed diagnostic criteria for PCOS, using the criteria of ovulatory dysfunction, hyperandrogenism, polycystic ovaries on ultrasound, and exclusion of other disorders in varying combinations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperandrogenism can be diagnosed clinically based upon the presence of hirsutism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acne. The clinical diagnosis is supported by laboratory evidence of hyperandrogenism, such as an elevated total, bioavailable, or free circulating testosterone or DHEA-S concentration.",
"   </p>",
"   <p>",
"    Women with PCOS who have the most severe insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/4\">",
"     4",
"    </a>",
"    ] and the most elevated testosterone concentrations are least likely to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    treatment. Specific interventions, such as weight loss may improve ovulatory response to clomiphene (",
"    <a class=\"graphic graphic_table graphicRef56718 \" href=\"UTD.htm?4/36/4684\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link&amp;anchor=H31#H31\">",
"     \"Ovulation induction with clomiphene citrate\", section on 'Infertility in PCOS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoid treatment can reduce DHEA-S levels and oral contraceptive pill pretreatment may reduce testosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=see_link\">",
"     \"Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    .) These interventions may improve the ovulatory response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Optimize body mass index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body mass index is calculated according to the following equation:",
"   </p>",
"   <p>",
"    BMI &nbsp;= &nbsp;body weight (in kg) &nbsp;&divide; &nbsp;stature (height, in meters) squared (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Women with PCOS and infertility often have a BMI greater than 27",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    Many case series have reported that losing weight can improve the ovulation rate of these women. As an example, one study evaluated the effects of weight loss in 20 women with a mean BMI of 32",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    amenorrhea for over three months, and abnormally increased androstenedione, testosterone,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dehydroepiandrosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/6\">",
"     6",
"    </a>",
"    ]. Dietary intervention, which consisted of caloric restriction to 1000 to 1500",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    and resulted in average weight loss of 9.7 kg (range 4.8 to 15.2 kg), was associated with a significant reduction in circulating testosterone and insulin concentrations. Many of the women ovulated (8 of 20) and some achieved a spontaneous pregnancy (4 of 20). Similar results have been reported by other investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Obesity and insulin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increase in energy expenditure (exercise) and a decrease in calorie consumption (dieting) are the best combination for achieving weight loss. Women with PCOS are often insulin resistant and some authorities believe that it is especially important for these insulin resistant women to avoid high glycemic index foods that tend to excessively stimulate pancreatic insulin secretion. We suggest all anovulatory women try to achieve a normal BMI when contemplating infertility treatment, both to enhance fertility and to improve pregnancy outcome. There are also general health benefits to being at a normal BMI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"     \"Role of physical activity and exercise in obese adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combination therapy with insulin sensitizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with PCOS and ovulatory infertility are insulin resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Obesity and insulin resistance'",
"    </a>",
"    .) Most women with a BMI greater than 27",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    or acanthosis nigricans have insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .) Elevated insulin secretion may directly stimulate ovarian androgen secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/12\">",
"     12",
"    </a>",
"    ], whereas reducing insulin secretion may lower ovarian androgen secretion, and increase the rate of spontaneous ovulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is an oral antihyperglycemic agent used primarily for the treatment of type 2 diabetes mellitus. It decreases blood glucose both by inhibiting hepatic glucose production and by increasing glucose utilization in the peripheral tissues. Metformin increases insulin sensitivity through mechanisms that have not been fully elucidated. Unlike the sulfonylureas, metformin does not cause hypoglycemia because it does not increase insulin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some randomized clinical trials have shown that the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    is effective for inducing ovulation in women with PCOS who have previously failed to conceive with clomiphene therapy alone. Although metformin may be effective for ovulation, a large, multicenter trial reported that live birth rates were significantly lower with metformin compared with clomiphene (alone or combined with metformin) due to higher early pregnancy losses. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link&amp;anchor=H14#H14\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Anovulatory infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current guidelines from a consensus group recommend that women who do not become pregnant with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    should be treated with gonadotropin injections or laparoscopic ovarian surgery (to reduce androgen secretion by the ovary) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/13\">",
"     13",
"    </a>",
"    ]. However, it is reasonable to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in carefully selected women with PCOS, infertility, and insulin resistance who have not responded to standard treatments, such as weight loss and clomiphene monotherapy, but who want to avoid the potential complications of more aggressive therapy. In two separate studies, combination clomiphene-metformin therapy appeared to result in similar ovulatory and pregnancy rates when compared with gonadotropin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/14\">",
"     14",
"    </a>",
"    ] and laparoscopic ovarian surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link&amp;anchor=H14#H14\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Anovulatory infertility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link&amp;anchor=H31#H31\">",
"     \"Ovulation induction with clomiphene citrate\", section on 'Infertility in PCOS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other insulin sensitizers have been approved by the FDA for the treatment of diabetes:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    . These agents have not been extensively studied for their effects on ovulation rates in women with PCOS. However, we suggest not using these drugs, as concern has been raised about their cardiovascular safety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not an insulin sensitizer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    , an alpha-glucosidase inhibitor used in the management of type 2 diabetes, has been studied in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -resistant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link&amp;anchor=H36#H36\">",
"     \"Ovulation induction with clomiphene citrate\", section on 'Alpha-glucosidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Combination therapy with glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulatory women in WHO group II (most of whom have PCOS), with DHEA-S levels greater than 2.0",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (mid-normal range), appear to have reduced ovulation and pregnancy rates when they are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    . Some studies suggest that treatment with clomiphene plus glucocorticoid improves pregnancy rates in these women.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    (5 mg hs) has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, 64 anovulatory infertile women were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    50 mg daily for cycle days five to nine or clomiphene 50 mg for cycle days five to nine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (0.5 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/5\">",
"     5",
"    </a>",
"    ]. If ovulation did not occur, the clomiphene dose was sequentially increased to 100 mg daily and then 150 mg daily. A significantly higher rate of ovulation and conception occurred in women who received both clomiphene plus dexamethasone and had a DHEA-S concentration greater than 2.0",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    compared with those who received clomiphene alone (ovulation 13 of 13 versus 6 of 12, conception 11 of 13 versus 4 of 12).",
"   </p>",
"   <p>",
"    In another trial in which 230",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -resistant women with PCOS and",
"    <strong>",
"     normal",
"    </strong>",
"    DHEA-S were randomly assigned to clomiphene (200 mg per day, cycle days 5 to 9) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (2 mg per day, cycle days 5 to 14), conception rates were 41 and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/16\">",
"     16",
"    </a>",
"    ] of these two trials, as well as a third [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/17\">",
"     17",
"    </a>",
"    ], concluded that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    significantly improved ovulation and pregnancy rates when compared with clomiphene alone (odds ratios 14.7 and 9.5 for ovulatory and pregnancy rates, respectively). However, there were important differences between trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One included only women who had never used",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/5\">",
"       5",
"      </a>",
"      ], while the others included only clomiphene resistant patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/14,17\">",
"       14,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest trial excluded women with high serum DHEAS [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/14\">",
"       14",
"      </a>",
"      ], while another did not [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      administered varied between studies (0.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      days 5 to 9 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/5\">",
"       5",
"      </a>",
"      ] or 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      days 3 to 12 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/14\">",
"       14",
"      </a>",
"      ] or 5 to 14 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/17\">",
"       17",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, current guidelines from a consensus group recommend that women with PCOS who do not become pregnant with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    should be treated with gonadotropin injections or laparoscopic ovarian surgery (to reduce androgen secretion by the ovary) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, depending upon the patient's preferences, the results of the meta-analysis reviewed above suggest that it is also reasonable to use combination treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in women with PCOS who have not conceived with clomiphene alone. Optimal dosing is not known, but the largest and best designed trial demonstrated benefit using dexamethasone 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    days 5 to 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/14\">",
"     14",
"    </a>",
"    ]. This approach may be used for women without regard to DHEA-S concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16487/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. If ovulation occurs, then treatment may be continued for three to six cycles. Dexamethasone should be discontinued upon diagnosis of pregnancy or if ovulation does not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic work-up of the infertile couple not pregnant within three months of use of standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    regimens should be reviewed to determine if further diagnostic investigation or another therapeutic approach is indicated. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Review the cause of infertility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For infertile women classified as World Health Organization II (relatively normal gonadotropin levels and evidence of significant endogenous estrogen production):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest weight loss for women with BMI greater than 27",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      to improve the likelihood of ovulation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Optimize body mass index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       Clomiphene",
"      </a>",
"      citrate is the first line infertility treatment for women with oligoovulation or anovulation who are normogonadotropic, normoprolactinemic, and euthyroid (eg, PCOS). Guidelines from a consensus group currently recommend that if clomiphene therapy is unsuccessful in women with PCOS, the next step should be exogenous gonadotropin therapy or laparoscopic ovarian surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link&amp;anchor=H31#H31\">",
"       \"Ovulation induction with clomiphene citrate\", section on 'Infertility in PCOS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      However, a patient's values and preferences should play an important role in determining treatment options. Therefore, for patients who place a high value on avoiding the higher multiple gestation rate and the risk of ovarian hyperstimulation associated with gonadotropin therapy, or potential surgical complications with laparoscopic surgery, it is reasonable to offer additional attempts at ovulation induction with combination medical therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although data are limited, women may benefit from the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , even if they have a normal serum DHEAS concentration. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Combination therapy with glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Metformin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/1\">",
"      Adashi, EY. Clomiphene citrate initiated ovulation. Semin Reprod Endocrinol 1986; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/2\">",
"      Gysler M, March CM, Mishell DR Jr, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982; 37:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/3\">",
"      Bates GW, Bates SR, Whitworth NS. Reproductive failure in women who practice weight control. Fertil Steril 1982; 37:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/4\">",
"      Murakawa H, Hasegawa I, Kurabayashi T, Tanaka K. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate. J Reprod Med 1999; 44:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/5\">",
"      Daly DC, Walters CA, Soto-Albors CE, et al. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 1984; 41:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/6\">",
"      Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/7\">",
"      Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 1982; 38:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/8\">",
"      Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994; 61:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/9\">",
"      Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/10\">",
"      Barbieri RL. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol 2000; 183:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/11\">",
"      Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983; 147:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/12\">",
"      Barbieri RL, Makris A, Randall RW, et al. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/13\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/14\">",
"      Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril 2002; 78:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/15\">",
"      Isaacs JD Jr, Lincoln SR, Cowan BD. Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. Fertil Steril 1997; 67:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/16\">",
"      Brown J, Farquhar C, Beck J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009; :CD002249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16487/abstract/17\">",
"      Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod 2006; 21:1805.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7406 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16487=[""].join("\n");
var outline_f16_6_16487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REVIEW THE CAUSE OF INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHO CLASSIFICATION OF ANOVULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OPTIONS FOR WOMEN WITH WHO TYPE II ANOVULATORY INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Optimize body mass index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combination therapy with insulin sensitizers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Combination therapy with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7406\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7406|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/36/4684\" title=\"table 1\">",
"      Multistep approach treatment infertility PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=related_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=related_link\">",
"      Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_6_16488="Acne nodules";
var content_f16_6_16488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57925%7EDERM%2F59878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57925%7EDERM%2F59878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acne nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe nodular acne on the forehead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules, pustules, and nodules are present on the face. This patient also has postinflammatory hyperpigmentation and scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16488=[""].join("\n");
var outline_f16_6_16488=null;
var title_f16_6_16489="Clinical manifestations and diagnosis of nocardiosis";
var content_f16_6_16489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of nocardiosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16489/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16489/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16489/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/6/16489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardiosis is an uncommon gram-positive bacterial infection caused by aerobic actinomycetes in the genus Nocardia. Nocardia spp have the ability to cause localized or systemic suppurative disease in humans and animals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Nocardiosis is typically regarded as an opportunistic infection, but approximately one-third of infected patients are immunocompetent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link&amp;anchor=H8#H8\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\", section on 'Immunocompromise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major clinical manifestations and diagnosis of nocardiosis will be reviewed here. Two characteristics of nocardiosis are its ability to disseminate to virtually any organ, particularly the central nervous system, and its tendency to relapse or progress despite appropriate therapy.",
"   </p>",
"   <p>",
"    The classification of nocardiosis is based upon the location and extent of disease and includes pulmonary, central nervous system, cutaneous, and disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Although there are no pathognomonic signs or symptoms of nocardiosis, it should be suspected in any patient who presents with brain, soft tissue, or cutaneous lesions, and a concurrent or recent pulmonary process.",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, pathogenesis, and treatment of Nocardia infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link\">",
"     \"Treatment of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of nocardial infection is increased in immunocompromised patients, particularly those with defects in cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/4\">",
"     4",
"    </a>",
"    ]. In a literature review of over 1000 cases, 64 percent of patients with nocardiosis were immunocompromised [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link&amp;anchor=H8#H8\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\", section on 'Immunocompromise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes of immunocompromise have included solid organ or hematopoietic stem cell transplantation, glucocorticoid therapy, HIV infection (especially if the CD4 count is &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3),",
"    </span>",
"    malignancy (most often after recent chemotherapy or glucocorticoid therapy), and diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5,7-10\">",
"     5,7-10",
"    </a>",
"    ]. Chronic lung disease and alcoholism are additional risk factors for pulmonary nocardiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a matched case-control study of organ transplant recipients, independent risk factors for nocardiosis were receipt of high-dose glucocorticoids, history of cytomegalovirus disease, and high levels of calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SITES OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best data on the sites of nocardial infection come from a 1994 literature review of 1050 cases of nocardiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic (&ge;2 sites involved) &mdash; 32 percent; among patients with systemic disease, 44 percent had CNS involvement",
"     </li>",
"     <li>",
"      Pulmonary (only) &mdash; 39 percent",
"     </li>",
"     <li>",
"      CNS (only) &mdash; 9 percent",
"     </li>",
"     <li>",
"      Cutaneous or lymphocutaneous &mdash; 8 percent",
"     </li>",
"     <li>",
"      Single site extrapulmonary (eg, eyes, bone) &mdash; 12 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are the primary site of nocardial infection in more than two-thirds of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/3\">",
"     3",
"    </a>",
"    ]. Nocardia spp are not normally found in the respiratory tract; as a result, isolation of Nocardia from the sputum is almost always indicative of infection. Most pulmonary infections are primary but Nocardia can spread to the lung from other sites, such as the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of pulmonary nocardiosis may be acute, subacute, or chronic and is not distinguished by any specific signs or symptoms. Fever, night sweats, fatigue, anorexia, weight loss, dyspnea, cough, hemoptysis, and pleuritic chest pain have all been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2-4,6,10,12\">",
"     2-4,6,10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although 20 percent of extrapulmonary Nocardia infections occur in the absence of pulmonary disease, approximately 50 percent of all pulmonary cases disseminate to sites outside the lungs, most commonly the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, complications such as empyema, mediastinitis, pericarditis, and superior vena cava syndrome can occur following contiguous spread of nocardial infection from a lung, pleural, or cutaneous focus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219372903\">",
"    <span class=\"h3\">",
"     Imaging findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multitude of imaging findings have been demonstrated in pulmonary nocardiosis, including single or multiple nodules, lung masses (with or without cavitation), reticulonodular infiltrates, interstitial infiltrates, lobar consolidation, subpleural plaques, and pleural effusions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77089 \" href=\"UTD.htm?31/36/32335\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65316 \" href=\"UTD.htm?30/26/31151\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. As a result, nocardiosis has frequently been misdiagnosed initially as tuberculosis (since upper lobe involvement is common and Nocardia spp are weakly acid-fast), invasive fungal disease, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Pulmonary nocardiosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardia appears to have special tropism for neural tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], as illustrated in the retrospective review of 1050 cases of nocardiosis cited above in which the CNS was involved in approximately 20 percent of cases overall and in 44 percent of disseminated cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5\">",
"     5",
"    </a>",
"    ]. Isolated CNS disease has been reported, but this probably represents dissemination from a resolved or transient pulmonary or cutaneous infection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52153 \" href=\"UTD.htm?14/12/14529\">",
"     image 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmark of CNS nocardiosis is formation of a parenchymal abscess that can occur in any region of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5,17,18\">",
"     5,17,18",
"    </a>",
"    ]. Signs and symptoms of nocardial brain abscess are diverse and nonspecific. Patients may present with fever, headache, meningismus, seizures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, typically those with intact immune systems, CNS nocardiosis remains clinically silent, at times persisting for years before a diagnosis is made [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5\">",
"     5",
"    </a>",
"    ]. CNS nocardiosis can present with symptoms suggesting a mass lesion without any symptoms typically associated with infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In such patients, nocardial brain abscess may be erroneously diagnosed as a primary or metastatic neoplasm prior to biopsy.",
"   </p>",
"   <p>",
"    Nocardial meningitis is an infrequent manifestation of CNS nocardiosis and can occur with or without an associated brain abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/22\">",
"     22",
"    </a>",
"    ]. In a case series of 28 episodes of nocardial meningitis, the clinical presentation was consistent with subacute or chronic meningitis characterized by fever (68 percent), meningismus (64 percent), headache (55 percent), and associated brain abscess (43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/23\">",
"     23",
"    </a>",
"    ]. The cerebrospinal fluid typically demonstrates a neutrophilic pleocytosis, hypoglycorrhachia, and elevated protein concentration, findings that are characteristic of bacterial meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four patterns of cutaneous disease have been observed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary cutaneous",
"     </li>",
"     <li>",
"      Lymphocutaneous",
"     </li>",
"     <li>",
"      Cutaneous involvement from a disseminated focus",
"     </li>",
"     <li>",
"      Mycetoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be prudent to assume that immunocompetent patients with cutaneous disease who do not have a clear history of antecedent trauma at the site of their infection, a mycetoma, or a sporotrichoid (lymphocutaneous) pattern of lesions have disseminated disease until proven otherwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Primary cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the skin is the primary site of nocardiosis, the infection results from direct inoculation of organisms into the skin, often during gardening or farming; in some cases, this occurs via puncture by a thorn or splinter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Inoculation can also occur via trauma, surgery, a vascular catheter, an insect bite [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/24\">",
"     24",
"    </a>",
"    ], or an animal scratch or bite.",
"   </p>",
"   <p>",
"    Nocardiosis is an uncommon cause of skin infection and is clinically indistinguishable from lesions produced by common pyogenic bacteria such as Staphylococcus aureus and group A streptococcus. Since most superficial skin infections are treated without a bacteriologic diagnosis, the true incidence of nocardial skin infection may be underestimated.",
"   </p>",
"   <p>",
"    Manifestations of primary cutaneous nocardiosis include ulcerations, pyoderma, cellulitis, nodules, and subcutaneous abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Cellulitis presents with pain, swelling, erythema, and warmth at the affected site, typically without associated drainage; cellulitis caused by Nocardia spp rarely disseminates to bone, muscles, or joints [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The diagnosis of nocardiosis as the etiologic agent of skin lesions will be delayed if a culture is not obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link\">",
"     \"Skin abscesses, furuncles, and carbuncles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lymphocutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymphocutaneous form of nocardiosis occurs when a primary nocardial skin infection involves the regional lymphatics, producing a nodular lymphangitis. A clinical picture identical to the lymphocutaneous syndrome caused by Sporothrix schenckii develops; this type of cutaneous involvement has been termed \"sporotrichoid nocardiosis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=see_link&amp;anchor=H5#H5\">",
"     \"Lymphangitis\", section on 'Nodular lymphangitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=see_link\">",
"     \"Clinical features and diagnosis of sporotrichosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cutaneous manifestations of disseminated nocardiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated nocardiosis presents with cutaneous skin lesions in approximately 2 percent of cases; these lesions may be the first sign of the disease (",
"    <a class=\"graphic graphic_picture graphicRef62568 \" href=\"UTD.htm?43/24/44430\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/32\">",
"     32",
"    </a>",
"    ]. Primary and secondary skin lesions cannot be distinguished based upon their appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mycetoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mycetoma is a chronic cutaneous infection that can be caused by fungi (eumycetoma) or members of the Actinomycetales order of bacteria, such as Nocardia spp (actinomycetoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/6\">",
"     6",
"    </a>",
"    ]. N. brasiliensis is the most common species of Nocardia to cause mycetoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the organism is inoculated into the skin, most commonly on the feet, legs, or back, a pyogenic response ensues, with formation of a painless nodule at the site of entry. As the nodule enlarges, a chronic inflammatory response occurs. Indurated lesions develop in an indolent fashion, with sinus tract formation exuding granules composed of clumped organisms. The enlarging granulomatous mass can remain localized or can extend, eventually involving muscle and bone. Once extension has occurred, mycetomas are frequently unresponsive to antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Disseminated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated nocardiosis is defined as two noncontiguous sites of involvement that may or may not include a pulmonary focus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2\">",
"     2",
"    </a>",
"    ]. Nocardia can disseminate from a pulmonary or cutaneous focus to virtually any organ [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]. Although dissemination is presumed to result from hematogenous spread, identifying Nocardia in blood cultures is uncommon due in part to their fastidious nature [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/33\">",
"     33",
"    </a>",
"    ]. To maximize the yield of Nocardia, blood cultures should be held for approximately four weeks. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Culture techniques and incubation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardia bacteremia is a rare occurrence. The presentation and risk factors for infection are similar to those in patients who are nonbacteremic; the only unique risk factor for bacteremia is an endovascular foreign body [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As an example, in one report, 10 of 17 cases of Nocardia bacteremia in cancer patients were associated with a central venous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/35\">",
"     35",
"    </a>",
"    ]. In a literature review of 36 cases of Nocardia bacteremia, approximately 30 percent had concomitant bacteremia with other pathogens, mostly gram-negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methods to maximize the yield of Nocardia on blood cultures are discussed below. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Culture techniques and incubation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly involved sites (other than pulmonary, CNS, and cutaneous) are bone, heart valves (primarily prosthetic valves), joints, and kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/5,6,36,37\">",
"     5,6,36,37",
"    </a>",
"    ]. In addition, numerous other sites of involvement have been reported including the sinuses, eyes, spleen, liver, adrenal glands, pancreas, thyroid gland, prostate, and testicles; Nocardia spp can also cause epidural abscess, postsurgical mediastinitis, implantable defibrillator pocket infection, and retroperitoneal and psoas abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2,3,6,38-51\">",
"     2,3,6,38-51",
"    </a>",
"    ]. When the original focus of infection cannot be identified, the patient is presumed to have resolved pulmonary or cutaneous disease.",
"   </p>",
"   <p>",
"    Primary infection can also result from inoculation of organisms into the eye, resulting in keratitis and endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/6,52-55\">",
"     6,52-55",
"    </a>",
"    ]. Nocardia endophthalmitis after cataract surgery is an aggressive disease with poor visual outcomes in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link\">",
"     \"Bacterial endophthalmitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no pathognomonic signs or symptoms of nocardiosis, it should be suspected in any patient who presents with brain, soft tissue, or cutaneous lesions, and a concurrent or recent pulmonary process.",
"   </p>",
"   <p>",
"    Nocardiosis has a broad range of clinical presentations and can present similarly to several other infections as well as malignancy. Many patients with nocardiosis are immunocompromised, necessitating empiric therapy upon presentation while a diagnosis is sought. The differential diagnosis varies with the site of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulmonary nocardiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of pulmonary nocardiosis includes the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fungal infection (eg, Aspergillus spp, zygomycosis [mucormycosis], Cryptococcus neoformans)",
"     </li>",
"     <li>",
"      Mycobacterial infection (eg, M. tuberculosis, M. avium intracellulare complex, M. kansasii)",
"     </li>",
"     <li>",
"      Bacterial infection (eg, Rhodococcus equi and gram-negative bacilli such as Pseudomonas aeruginosa and Klebsiella pneumoniae)",
"     </li>",
"     <li>",
"      Malignancy (eg, primary lung cancer, lung metastases)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     CNS nocardiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of CNS nocardiosis includes the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other causes of bacterial brain abscess, including anaerobic bacteria",
"     </li>",
"     <li>",
"      Fungal infection (eg, Aspergillus spp, Cryptococcus neoformans, Coccidioides immitis, zygomycosis [mucormycosis])",
"     </li>",
"     <li>",
"      Parasitic infection (eg, Toxoplasmosis, Cysticercosis).",
"     </li>",
"     <li>",
"      Malignancy (eg, primary CNS lymphoma, CNS metastases)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683292219\">",
"    <span class=\"h2\">",
"     Cutaneous nocardiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cutaneous nocardiosis includes the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fungal infection (eg, Aspergillus spp, Cryptococcus spp, Scedosporium",
"      <span class=\"nowrap\">",
"       apiospermum/Pseudallescheria",
"      </span>",
"      boydii, Sporothrix schenckii)",
"     </li>",
"     <li>",
"      Nontuberculous mycobacterial infection (particularly the rapidly growing nontuberculous mycobacteria, Mycobacterium chelonae and M. fortuitum, and the intermediately growing mycobacterium, M. marinum)",
"     </li>",
"     <li>",
"      Bacterial infection (eg, Erysipelothrix rhusiopathiae and Francisella tularensis, which causes tularemia)",
"     </li>",
"     <li>",
"      Parasitic infection (eg, cutaneous leishmaniasis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42537?source=see_link\">",
"     \"Infectious causes of fever and rash in non-HIV immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of nocardiosis requires the isolation and identification of the organism from a clinical specimen. Delay in establishing the correct diagnosis is common due to the nonspecific and diverse clinical presentation of nocardiosis and the inherent difficulty in cultivating Nocardia. The mean time from the development of symptoms to diagnosis has, in different studies, ranged from 42 days to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/10,56\">",
"     10,56",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Appropriate specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The difficulty in establishing a diagnosis of nocardiosis may be related to the inadequacy of specimens obtained by noninvasive means. In one case series, 44 percent of pulmonary infections required an invasive procedure to establish the diagnosis of nocardiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/56\">",
"     56",
"    </a>",
"    ]. When an invasive procedure is performed, cultures are positive in 85 to 90 percent of specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even when adequate specimens are obtained, recovery of Nocardia in the laboratory can be difficult. Thus, when Nocardia infection is suspected, the clinical laboratory should be notified so that specific media and staining procedures can be performed on submitted samples. Certain sputum decontamination solutions have been shown to be toxic to Nocardia spp, particularly sodium hydroxide, N-acetylcysteine and benzalkonium chloride&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. These solutions should be avoided when isolation of Nocardia is attempted. Examination of clinical specimens for Nocardia should include macroscopic examination for granules, which when found can be crushed for microscopic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Gram stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardia spp appear as delicate, filamentous, sometimes beaded [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/1\">",
"     1",
"    </a>",
"    ], branching gram-positive rods in clinical specimens (",
"    <a class=\"graphic graphic_picture graphicRef80426 \" href=\"UTD.htm?15/61/16336\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Modified acid-fast staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the proper clinical setting, a presumptive diagnosis of nocardiosis can be made if partially acid-fast filamentous branching rods are visualized in clinical specimens. The value of direct examination of specimens cannot be overemphasized, since early diagnosis and treatment of nocardiosis have been associated with improved clinical outcomes in some patient groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/12,58\">",
"     12,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acid-fast nature of Nocardia is most reliably demonstrated when organisms are stained by a modified Kinyoun procedure (",
"    <a class=\"graphic graphic_picture graphicRef66920 \" href=\"UTD.htm?39/30/40417\">",
"     picture 3",
"    </a>",
"    ). This method substitutes 1 percent sulfuric acid for acid alcohol as a decolorizer, which allows the less tenaciously acid-fast Nocardia to retain fuchsin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/6\">",
"     6",
"    </a>",
"    ]. The acid-fast staining property of Nocardia is often lost in older cultures.",
"   </p>",
"   <p>",
"    The acid-fast reaction and the aerial branching of mycelial-like structures extending from the agar surface are simple tests that differentiate Nocardia from other aerobic and anaerobic actinomyces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Culture techniques and incubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most routine aerobic bacterial, fungal, and mycobacterial culture media can support Nocardia. However, selective media, such as buffered charcoal yeast extract (the media used for the isolation of Legionella spp) and modified Thayer-Martin agar may be beneficial in decreasing the overgrowth of other organisms in specimens derived from non-sterile sites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In routine aerobic cultures, Nocardia spp have variable colonial morphology, from chalky white to pigment-producing orange, yellow, or brown colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/1\">",
"     1",
"    </a>",
"    ], and usually require 5 to 21 days for growth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/3,5,59\">",
"     3,5,59",
"    </a>",
"    ]. Since most routine fluid or tissue cultures are discarded at 48 to 72 hours, laboratory personnel must be notified when nocardiosis is suspected in order to ensure an adequate incubation period.",
"   </p>",
"   <p>",
"    Although Nocardia spp can be recovered in most blood culture systems, this rarely occurs despite frequent hematogenous dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/33\">",
"     33",
"    </a>",
"    ]. Most cases of bacteremia are associated with endovascular devices, such as central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Thus, blood cultures should be considered for patients with endovascular devices who remain febrile despite appropriate therapy or have evidence of embolic disease. Blood cultures should be held for up to two to four weeks, with blind subculture to selective media [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/59\">",
"     59",
"    </a>",
"    ]. Communication by the clinician with the laboratory is essential to maximize the yield of Nocardia from blood cultures. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Bacteremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Speciation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speciation of Nocardia is difficult. The hydrolysis of casein and the decomposition of tyrosine, xanthine, and hypoxanthine are older methods that have been used. However, these tests require an additional two weeks to complete and are not precise in differentiating between the most recently described species of Nocardia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro susceptibility studies have shown that different Nocardia species and strains often have markedly different susceptibility patterns, underlining the importance of obtaining speciation and susceptibility testing of all clinical isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2,60-64\">",
"     2,60-64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Susceptibility testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additionally, virulence potential may also vary among different Nocardia species. As an example, Nocardia farcinica is the most common species within the Nocardia asteroides complex and may also be more virulent than the other members of the complex [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Identification of N. farcinica is important because this species characteristically demonstrates resistance to third-generation cephalosporins and is often resistant to imipenem [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/4,59\">",
"     4,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of nocardiosis\", section on 'Antibiotic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) for identification of Nocardia spp provides more accurate and rapid results than the conventional methods using biochemical and susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/4,59,65,68-70\">",
"     4,59,65,68-70",
"    </a>",
"    ]. However, PCR is not available in most clinical laboratories.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of a 16S rRNA-based PCR assay was examined using 18 samples (eg, skin biopsies, abscess material, sputum, and bronchoalveolar lavage fluid) from patients with nocardiosis diagnosed by conventional cultures and 20 clinical samples from patients with confirmed tuberculosis as negative controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/69\">",
"     69",
"    </a>",
"    ]. All specimens from patients with nocardiosis were positive while none of the 20 control samples were positive, confirming the sensitivity and specificity of the primers and PCR protocol. In addition, sequencing allowed specific identification to the species level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility testing should be performed on all clinically significant isolates since different Nocardia species and strains often have markedly different susceptibility patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/4,59,71\">",
"     4,59,71",
"    </a>",
"    ]. This is particularly important because most patients with nocardiosis are immunocompromised, the CNS is frequently involved, and there is a high mortality rate of untreated or inadequately treated infection. Furthermore,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) intolerance is common, which can necessitate switching to alternate agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of nocardiosis\", section on 'Antibiotic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal method for antimicrobial susceptibility testing, as recommended by the Clinical and Laboratory Standards Institute (CLSI, formerly the National Committee for Clinical Laboratory Standards [NCCLS]) is the microdilution method [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/71\">",
"     71",
"    </a>",
"    ]. Despite the availability of this technique in hospital laboratories, the minimum inhibitory concentration (MIC) of antimicrobials can be difficult to interpret. It is therefore recommended that isolates of Nocardia be sent to a reference laboratory for precise identification and confirmation of susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reference laboratories that perform Nocardia spp culture and susceptibility testing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mayo Medical Laboratories;",
"      <a class=\"external\" href=\"file://www.mayomedicallaboratories.com/\">",
"       www.mayomedicallaboratories.com",
"      </a>",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       Mycobacteria/Nocardia",
"      </span>",
"      Research Laboratory, The University of Texas Health Science Center;",
"      <a class=\"external\" href=\"file://www.uthct.edu/\">",
"       www.uthct.edu",
"      </a>",
"     </li>",
"     <li>",
"      The University of Pennsylvania Health System;",
"      <a class=\"external\" href=\"file://www.uphs.upenn.edu/\">",
"       www.uphs.upenn.edu",
"      </a>",
"     </li>",
"     <li>",
"      ARUP Laboratories, University of Utah;",
"      <a class=\"external\" href=\"file://www.aruplab.com/index.jsp\">",
"       www.aruplab.com/index.jsp",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As recommended by CLSI, the following drugs are tested by microdilution:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    (which also predicts",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    susceptibility), sulfamethoxazole or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The E-test method of susceptibility testing has been considered by some authors as an appropriate alternative method for susceptibility testing of Nocardia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16489/abstract/1,72\">",
"     1,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic susceptibility patterns in the different Nocardia spp are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of nocardiosis\", section on 'Antibiotic susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardia spp, especially N. asteroides complex, have a propensity to cause brain infection. Thus, the presence of any symptoms indicative of CNS disease warrants brain imaging (computed tomography or magnetic resonance imaging) to exclude the presence of a brain abscess (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78604 \" href=\"UTD.htm?4/57/5010\">",
"     image 4",
"    </a>",
"    ). In addition, all immunocompromised patients with cutaneous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary nocardiosis, even those without symptoms of CNS involvement, should undergo brain imaging. Immunocompetent patients with pulmonary nocardiosis should also undergo radiographic evaluation to exclude CNS infection. Immunocompetent patients with primary cutaneous nocardiosis only rarely have disseminated disease and the decision regarding brain imaging should be made on an individual basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocardiosis is caused by an aerobic actinomycete in the genus Nocardia, an unusual gram-positive bacteria. Nocardial infection most often occurs in immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common disease sites are the lung, central nervous system (CNS), and skin. There are no pathognomonic signs or symptoms for nocardiosis. It should be suspected in any patient who presents with brain, soft tissue, or cutaneous lesions, and a concurrent or recent pulmonary process.",
"     </li>",
"     <li>",
"      The lungs are the primary site of nocardial infection in more than two-thirds of cases. The onset of pulmonary nocardiosis may be acute, subacute, or chronic and is not distinguished by any specific signs or symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic findings of lung involvement are variable and include single or multiple nodules, lung masses (with or without cavitation), reticulonodular infiltrates, interstitial infiltrates, lobar consolidation, subpleural plaques, and pleural effusions (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77089 \" href=\"UTD.htm?31/36/32335\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65316 \" href=\"UTD.htm?30/26/31151\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CNS disease accounts for approximately 20 percent of Nocardia cases and most commonly results from dissemination of infection from a pulmonary or cutaneous site. The hallmark of CNS nocardiosis is formation of a parenchymal abscess that can occur in any region of the brain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Central nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Four patterns of cutaneous disease occur: primary cutaneous, lymphocutaneous, cutaneous involvement from a disseminated focus, and mycetoma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cutaneous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cutaneous disease results from the direct inoculation of organisms into the skin from trauma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Primary cutaneous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated nocardiosis is defined as two or more noncontiguous sites of involvement that may or may not include a pulmonary focus. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Disseminated infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A definitive diagnosis of nocardiosis requires the isolation and identification of the organism from a clinical specimen. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Establishing a diagnosis of nocardiosis is problematic since an invasive procedure is often required to obtain an adequate specimen and recovery of Nocardia in the laboratory is difficult because of its slow growth. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Appropriate specimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the proper clinical setting, a presumptive diagnosis of nocardiosis can be made if partially acid-fast filamentous branching rods are visualized in clinical specimens. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Modified acid-fast staining'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nocardia in routine aerobic cultures usually require 5 to 21 days for growth. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Culture techniques and incubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Precise speciation and susceptibility testing of clinical isolates is important because resistance patterns vary by species. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Speciation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymerase chain reaction provides more accurate and rapid results for the diagnosis of nocardiosis than the conventional methods but is not available in most clinical laboratories. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Polymerase chain reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nocardia isolates are usually sent to a reference laboratory for precise identification and susceptibility testing. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the propensity for Nocardia spp to cause central nervous system infection, brain imaging should be performed in all immunocompromised patients and in all patients with pulmonary nocardiosis. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Imaging studies'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/1\">",
"      Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006; 19:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/2\">",
"      Lerner PI. Nocardiosis. Clin Infect Dis 1996; 22:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/3\">",
"      Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore) 2004; 83:300.",
"     </a>",
"    </li>",
"    <li>",
"     Sorrel TC, Mitchell DH, Iredell JR, Chen SC-A. Nocardia Species. In: Principles and Practice of Infectious Diseases, 7th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. p.3199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/5\">",
"      Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev 1994; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/6\">",
"      McNeil MM, Brown JM. The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev 1994; 7:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/7\">",
"      Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/8\">",
"      Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol 2003; 41:4497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/9\">",
"      Castro JG, Espinoza L. Nocardia species infections in a large county hospital in Miami: 6 years experience. J Infect 2007; 54:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/10\">",
"      Mart&iacute;nez Tom&aacute;s R, Men&eacute;ndez Villanueva R, Reyes Calzada S, et al. Pulmonary nocardiosis: risk factors and outcomes. Respirology 2007; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/11\">",
"      Kahn FW, Gornick CC, Tofte RW. Primary cutaneous Nocardia asteroides infection with dissemination. Am J Med 1981; 70:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/12\">",
"      Uttamchandani RB, Daikos GL, Reyes RR, et al. Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome. Clin Infect Dis 1994; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/13\">",
"      Poland GA, Jorgensen CR, Sarosi GA. Nocardia asteroides pericarditis: report of a case and review of the literature. Mayo Clin Proc 1990; 65:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/14\">",
"      Kessler R, Follis F, Daube D, Wernly J. Constrictive pericarditis from Nocardia asteroides infection. Ann Thorac Surg 1991; 52:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/15\">",
"      Abdelkafi S, Dubail D, Bosschaerts T, et al. Superior vena cava syndrome associated with Nocardia farcinica infection. Thorax 1997; 52:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/16\">",
"      Hwang JH, Koh WJ, Suh GY, et al. Pulmonary nocardiosis with multiple cavitary nodules in a HIV-negative immunocompromised patient. Intern Med 2004; 43:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/17\">",
"      Sabuncuo��lu H, Cibali A&ccedil;ikgo Z Z, Caydere M, et al. Nocardia farcinica brain abscess: a case report and review of the literature. Neurocirugia (Astur) 2004; 15:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/18\">",
"      Yildiz O, Alp E, Tokgoz B, et al. Nocardiosis in a teaching hospital in the Central Anatolia region of Turkey: treatment and outcome. Clin Microbiol Infect 2005; 11:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/19\">",
"      Mamelak AN, Obana WG, Flaherty JF, Rosenblum ML. Nocardial brain abscess: treatment strategies and factors influencing outcome. Neurosurgery 1994; 35:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/20\">",
"      Menk&uuml; A, Kurtsoy A, Tucer B, et al. Nocardia brain abscess mimicking brain tumour in immunocompetent patients: report of two cases and review of the literature. Acta Neurochir (Wien) 2004; 146:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/21\">",
"      Yamada SM, Nakai E, Toyonaga S, et al. A rapidly enlarging nocardial brain abscess mimicking malignant glioma. J Nippon Med Sch 2005; 72:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/22\">",
"      Chow E, Moore T, Deville J, Nielsen K. Nocardia asteroides brain abscesses and meningitis in an immunocompromized 10-year-old child. Scand J Infect Dis 2005; 37:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/23\">",
"      Bross JE, Gordon G. Nocardial meningitis: case reports and review. Rev Infect Dis 1991; 13:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/24\">",
"      Paredes BE, Hunger RE, Braathen LR, Brand CU. Cutaneous nocardiosis caused by Nocardia brasiliensis after an insect bite. Dermatology 1999; 198:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/25\">",
"      Satterwhite TK, Wallace RJ Jr. Primary cutaneous nocardiosis. JAMA 1979; 242:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/26\">",
"      Shimizu T, Furumoto H, Asagami C, et al. Disseminated subcutaneous Nocardia farcinica abscesses in a nephrotic syndrome patient. J Am Acad Dermatol 1998; 38:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/27\">",
"      Kil EH, Tsai CL, Kwark EH, Goldwasser J. A case of nocardiosis with an uncharacteristically long incubation period. Cutis 2005; 76:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/28\">",
"      Smego RA Jr, Gallis HA. The clinical spectrum of Nocardia brasiliensis infection in the United States. Rev Infect Dis 1984; 6:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/29\">",
"      Tsuboi R, Takamori K, Ogawa H, et al. Lymphocutaneous nocardiosis caused by Nocardia asteroides. Case report and literature review. Arch Dermatol 1986; 122:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/30\">",
"      Smego RA Jr, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore) 1999; 78:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/31\">",
"      Inamadar AC, Palit A, Peerapur BV, Rao SD. Sporotrichoid nocardiosis caused by Nocardia nova in a patient infected with human immunodeficiency virus. Int J Dermatol 2004; 43:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/32\">",
"      Threlkeld SC, Hooper DC. Update on management of patients with Nocardia infection. Curr Clin Top Infect Dis 1997; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/33\">",
"      Kontoyiannis DP, Ruoff K, Hooper DC. Nocardia bacteremia. Report of 4 cases and review of the literature. Medicine (Baltimore) 1998; 77:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/34\">",
"      Matulionyte R, Rohner P, U&ccedil;kay I, et al. Secular trends of nocardia infection over 15 years in a tertiary care hospital. J Clin Pathol 2004; 57:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/35\">",
"      Al Akhrass F, Hachem R, Mohamed JA, et al. Central venous catheter-associated Nocardia bacteremia in cancer patients. Emerg Infect Dis 2011; 17:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/36\">",
"      Kahraman S, Genctoy G, Arici M, et al. Septic arthritis caused by Nocardia asteroides in a renal transplant recipient. Transplant Proc 2004; 36:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/37\">",
"      Subha ST, Raman R. Nocardia infection of the mastoid in an immunocompromised patient. Med J Malaysia 2004; 59:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/38\">",
"      Wenger PN, Brown JM, McNeil MM, Jarvis WR. Nocardia farcinica sternotomy site infections in patients following open heart surgery. J Infect Dis 1998; 178:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/39\">",
"      Lalitha P, Tiwari M, Prajna NV, et al. Nocardia keratitis: species, drug sensitivities, and clinical correlation. Cornea 2007; 26:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/40\">",
"      Yin X, Liang S, Sun X, et al. Ocular nocardiosis: HSP65 gene sequencing for species identification of Nocardia spp. Am J Ophthalmol 2007; 144:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/41\">",
"      Roberts SA, Bartley J, Braatvedt G, Ellis-Pegler RB. Nocardia asteroides as a cause of sphenoidal sinusitis: case report. Clin Infect Dis 1995; 21:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/42\">",
"      Arabi Y, Fairfax MR, Szuba MJ, et al. Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Diagn Microbiol Infect Dis 1996; 24:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/43\">",
"      Carriere C, Marchandin H, Andrieu JM, et al. Nocardia thyroiditis: unusual location of infection. J Clin Microbiol 1999; 37:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/44\">",
"      P&oacute;lay A, Pep&oacute; J, Zsolt J, Kov&aacute;cs G. [Nocardia infections following heart operations]. Dermatol Monatsschr 1973; 159:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/45\">",
"      Atalay B, Azap O, Cekinmez M, et al. Nocardial epidural abscess of the thoracic spinal cord and review of the literature. J Infect Chemother 2005; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/46\">",
"      Routh JC, Lischer GH, Leibovich BC. Epididymo-orchitis and testicular abscess due to Nocardia asteroides complex. Urology 2005; 65:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/47\">",
"      Verghese S, Kurian VM, Maria CF, et al. Nocardia asteroides mediastinitis complicating coronary artery bypass surgery. J Assoc Physicians India 2003; 51:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/48\">",
"      Boell K, Gotoff R, Foltzer M, et al. Implantable defibrillator pocket infection and bacteremia caused by Nocardia nova complex isolate. J Clin Microbiol 2003; 41:5325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/49\">",
"      O'Rourke S, Kapoor S, Carter-Adkins D, Pachulski RT. ICD nocardiosis. J Interv Cardiol 2003; 16:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/50\">",
"      Qu L, Strollo DC, Bond G, Kusne S. Nocardia prostatitis in a small intestine transplant recipient. Transpl Infect Dis 2003; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/51\">",
"      Smit LH, Leemans R, Overbeek BP. Nocardia farcinica as the causative agent in a primary psoas abscess in a previously healthy cattle inspector. Clin Microbiol Infect 2003; 9:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/52\">",
"      Chaidaroon W, Tantayakom T. Nocardia keratitis in a human immunodeficiency virus patient. Jpn J Ophthalmol 2004; 48:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/53\">",
"      Eggink CA, Wesseling P, Boiron P, Meis JF. Severe keratitis due to Nocardia farcinica. J Clin Microbiol 1997; 35:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/54\">",
"      Haripriya A, Lalitha P, Mathen M, et al. Nocardia endophthalmitis after cataract surgery: clinicomicrobiological study. Am J Ophthalmol 2005; 139:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/55\">",
"      Hudson JD, Danis RP, Chaluvadi U, Allen SD. Posttraumatic exogenous Nocardia endophthalmitis. Am J Ophthalmol 2003; 135:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/56\">",
"      Georghiou PR, Blacklock ZM. Infection with Nocardia species in Queensland. A review of 102 clinical isolates. Med J Aust 1992; 156:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/57\">",
"      Palmer DL, Harvey RL, Wheeler JK. Diagnostic and therapeutic considerations in Nocardia asteroides infection. Medicine (Baltimore) 1974; 53:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/58\">",
"      Simpson GL, Stinson EB, Egger MJ, Remington JS. Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis 1981; 3:492.",
"     </a>",
"    </li>",
"    <li>",
"     Conville PS, Witebsky FG. Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and other Aerobic Actinomycetes. In: Manual of Clinical Microbiology, 9th Ed, Murray PR, Baron EJ, Jorgensen JH, et al (Eds), ASM Press, Washington, DC 2007. p.515.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/60\">",
"      Wallace RJ Jr, Steele LC, Sumter G, Smith JM. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother 1988; 32:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/61\">",
"      Boiron P, Provost F. In-vitro susceptibility testing of Nocardia spp. and its taxonomic implication. J Antimicrob Chemother 1988; 22:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/62\">",
"      Wallace RJ Jr, Brown BA, Tsukamura M, et al. Clinical and laboratory features of Nocardia nova. J Clin Microbiol 1991; 29:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/63\">",
"      Khardori N, Shawar R, Gupta R, et al. In vitro antimicrobial susceptibilities of Nocardia species. Antimicrob Agents Chemother 1993; 37:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/64\">",
"      Cercenado E, Mar&iacute;n M, S&aacute;nchez-Mart&iacute;nez M, et al. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrob Agents Chemother 2007; 51:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/65\">",
"      Wauters G, Avesani V, Charlier J, et al. Distribution of nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol 2005; 43:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/66\">",
"      Mu&ntilde;oz J, Mirelis B, Arag&oacute;n LM, et al. Clinical and microbiological features of nocardiosis 1997-2003. J Med Microbiol 2007; 56:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/67\">",
"      Torres OH, Domingo P, Pericas R, et al. Infection caused by Nocardia farcinica: case report and review. Eur J Clin Microbiol Infect Dis 2000; 19:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/68\">",
"      Brown JM, Pham KN, McNeil MM, Lasker BA. Rapid identification of Nocardia farcinica clinical isolates by a PCR assay targeting a 314-base-pair species-specific DNA fragment. J Clin Microbiol 2004; 42:3655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/69\">",
"      Couble A, Rodr&iacute;guez-Nava V, de Montclos MP, et al. Direct detection of Nocardia spp. in clinical samples by a rapid molecular method. J Clin Microbiol 2005; 43:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/70\">",
"      Cloud JL, Conville PS, Croft A, et al. Evaluation of partial 16S ribosomal DNA sequencing for identification of nocardia species by using the MicroSeq 500 system with an expanded database. J Clin Microbiol 2004; 42:578.",
"     </a>",
"    </li>",
"    <li>",
"     National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard. NCCLS document M24-A, National Committee for Clinical Laboratory Standards, Wayne, PA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16489/abstract/72\">",
"      Biehle JR, Cavalieri SJ, Saubolle MA, Getsinger LJ. Comparative evaluation of the E test for susceptibility testing of Nocardia species. Diagn Microbiol Infect Dis 1994; 19:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5515 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16489=[""].join("\n");
var outline_f16_6_16489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SITES OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H219372903\">",
"      - Imaging findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Primary cutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lymphocutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cutaneous manifestations of disseminated nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mycetoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Disseminated infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulmonary nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CNS nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H683292219\">",
"      Cutaneous nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Appropriate specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Modified acid-fast staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Culture techniques and incubation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Speciation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5515|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/36/32335\" title=\"diagnostic image 1\">",
"      Lung nodules in nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/26/31151\" title=\"diagnostic image 2\">",
"      Lung infiltrates in nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/12/14529\" title=\"diagnostic image 3\">",
"      CNS nocardiosis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/57/5010\" title=\"diagnostic image 4\">",
"      Nocardial brain abscess MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5515|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/24/44430\" title=\"picture 1\">",
"      Cutaneous nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/61/16336\" title=\"picture 2\">",
"      Nocardia on Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/30/40417\" title=\"picture 3\">",
"      Nocardia on modified AFB stain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42537?source=related_link\">",
"      Infectious causes of fever and rash in non-HIV immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=related_link\">",
"      Lymphangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=related_link\">",
"      Treatment of nocardiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_6_16490="Clinical manifestations of polycystic ovary syndrome in adults";
var content_f16_6_16490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of polycystic ovary syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16490/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16490/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16490/contributors\">",
"     David A Ehrmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16490/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16490/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16490/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/6/16490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/6/16490/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/6/16490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polycystic ovary syndrome (PCOS) is an important cause of both menstrual irregularity and androgen excess in women. When fully expressed, the manifestations include irregular menstrual cycles together with hirsutism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acne; obesity is a frequent concomitant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of PCOS will be reviewed here. The epidemiology and pathogenesis, diagnostic criteria for, and treatment of PCOS are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although prevalence data are limited, PCOS is thought to be one of the most common endocrinopathies in women, affecting between 6.5 and 8 percent of women overall [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of PCOS is strikingly similar across populations of women of reproductive age, being 6.6, 6.8, and 6.7 percent in the southeastern United States, the Greek island of Lesbos, and Spain, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The epidemiology of PCOS is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to appreciate that PCOS is a syndrome, reflecting multiple potential etiologies and variable clinical presentations. The key features of PCOS are oligo- or anovulation and hyperandrogenism. Women with PCOS may also have polycystic ovaries on pelvic ultrasonography, infertility due to oligoovulation, obesity, and insulin resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Menstrual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The menstrual dysfunction in PCOS is characterized by oligo- or amenorrhea and, therefore, infrequent or absent ovulation. The menstrual disturbances in PCOS classically have a peripubertal onset. Affected women may have a normal or slightly delayed menarche followed by irregular cycles. Other women may apparently have regular cycles at first and subsequently develop menstrual irregularity in association with weight gain. Although the mechanism is not fully elucidated, many obese women with PCOS resume more regular menstrual cycles after relatively small amounts of weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'Weight reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Endometrial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction in ovulatory events in PCOS leads to deficient progesterone secretion. Thus, women with PCOS may have constant mitogenic stimulation of the endometrium (chronic estrogen stimulation, no progesterone for differentiation) leading to intermittent breakthrough bleeding and dysfunctional uterine bleeding (frequent or unusually heavy menstrual bleeding typically associated with anovulation).",
"   </p>",
"   <p>",
"    The chronic unopposed estrogen exposure in PCOS may result in an excess risk of endometrial hyperplasia and endometrial carcinoma, although epidemiologic evidence for this association is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, women with PCOS do have other risk factors for endometrial cancer including chronic hyperinsulinemia, increased serum insulin-like growth factor (IGF-1) concentrations, hyperandrogenemia, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is no consensus on monitoring for endometrial hyperplasia in these patients, one study suggested that in oligoovulatory women with PCOS, an endometrial thickness &lt;7 mm on transvaginal ultrasound was not associated with endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Anovulatory infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility was included in the original description of PCOS by Stein and Leventhal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/9\">",
"     9",
"    </a>",
"    ]. Women with PCOS have infrequent ovulation, and therefore take longer to conceive. Many, if not most, women who have PCOS and oligoovulation and desire fertility eventually undergo ovulation induction therapies. Women who have PCOS may have other reasons for infertility as well, since they have, in comparison to women with hypothalamic amenorrhea, a reduced rate of conception relative to the rate of ovulation after therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many studies have also described an increased rate of early pregnancy loss in PCOS, the mechanism of which is poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8298?source=see_link&amp;anchor=H19#H19\">",
"     \"Definition and etiology of recurrent pregnancy loss\", section on 'Polycystic ovary syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hyperandrogenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperandrogenism is the second defining characteristic of PCOS. This is manifested clinically by hirsutism, acne, and male pattern balding. In rare instances, increased muscle mass, deepening of the voice, or clitoromegaly may occur, but these findings are suggestive of other causes of virilization, such as a neoplasm of the ovary or adrenal gland.",
"   </p>",
"   <p>",
"    Hirsutism is defined as excess terminal (thick, pigmented) body hair in a male distribution, and is commonly noted on the upper lip, chin, around the nipples (periareolar), and along the linea alba of the lower abdomen (",
"    <a class=\"graphic graphic_picture graphicRef73544 \" href=\"UTD.htm?5/5/5203\">",
"     picture 1",
"    </a>",
"    ). The approach to evaluation and management of hirsutism, including the 2008 Endocrine Society Clinical Guidelines, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescent hyperandrogenemia is considered to be an early manifestation of adult PCOS, and clinical manifestations of PCOS often have a peripubertal onset. Two studies of peripubertal girls suggest that obesity contributes to the hyperandrogenemia, as increasing body mass index (BMI) was associated with increases in serum total T, free T, and DHEA-S concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the androgen measured and the technique employed, between 50 and 90 percent of PCOS women have elevated serum androgen levels (",
"    <a class=\"graphic graphic_figure graphicRef72842 \" href=\"UTD.htm?21/25/21918\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/13\">",
"     13",
"    </a>",
"    ]. The adrenal cortex can contribute to the excess androgens derived from the ovary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=see_link\">",
"     \"Steroid hormone metabolism in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of hyperandrogenemia in PCOS is not known. However, in a cross-sectional study of 84 women with PCOS, the women between the ages of 42 and 47 had total and non-SHBG-bound testosterone levels that were 50 percent lower than those in women between the ages of 20 and 42 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/14\">",
"     14",
"    </a>",
"    ]. After age 47, androgen levels remained stable, although they were high compared with a group of control women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ovarian abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key ovarian findings in PCOS include multiple small pre-antral and antral follicles in a peripheral location, with an increased volume of stroma. Histologically, there is a thickened and sclerotic cortex of the ovary, giving the appearance of a smooth white capsule on gross examination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ultrasound appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;With new high frequency transvaginal ultrasonography, the histologic findings can be corroborated noninvasively. The historical ultrasound criteria for polycystic ovaries includes the presence of 8 to 10 small (2 to 8 mm) follicles in a peripheral array around an increased amount of stroma relative to the number of follicles; ovarian volume is also increased on average [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/16\">",
"     16",
"    </a>",
"    ]. This classic appearance does not refer to large cysts that might rupture or cause pain.",
"   </p>",
"   <p>",
"    A modified set of diagnostic criteria for PCOS (the Rotterdam criteria) have been published and are described in detail elsewhere. The Rotterdam ultrasound criteria include the presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased ovarian volume (&gt;10 mL; calculated using the formula 0.5 x length x width x thickness). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using the original ultrasound criteria in combination with an ovarian volume greater than 10 mL (from revised criteria), nearly all women with irregular menses and hyperandrogenism have polycystic ovaries on ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultrasound appearance of PCOS, using the historical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/16\">",
"     16",
"    </a>",
"    ], has been found in different studies in a number of different settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 92 percent of women with idiopathic hirsutism [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 87 percent with oligomenorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 82 percent of premenopausal women with type 2 diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 82 percent of women with congenital adrenal hyperplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 26 percent of women with amenorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 40 percent of women with a history of gestational diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 23 percent of women who considered themselves normal and reported regular menstrual cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 67 percent of women with androgenic alopecia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, as a sole finding, sonographically detected polycystic ovaries are not sufficient to make the diagnosis of PCOS, although they may represent a mild form of ovarian hyperandrogenism and insulin resistance. This was illustrated in a study of 68 nonhirsute women with normal menstrual cycles, 39 of whom had polycystic morphology on ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/23\">",
"     23",
"    </a>",
"    ]. Serum total and free testosterone and DHEAS were higher in the early follicular phase in women with polycystic morphology compared with those with normal ovarian morphology. In addition, both fasting insulin and insulin resistance calculated from a homeostasis model assessment of insulin resistance (HOMA-IR or HOMA model: fasting glucose x fasting insulin) were higher in the women with polycystic morphology.",
"   </p>",
"   <p>",
"    In a follow-up report from the same investigators, women with regular menstrual cycles and polycystic ovaries on ultrasound were not at increased risk for subsequent development of PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Follicular development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular development and function are abnormal in PCOS ovaries, including abnormal patterns of follicular fluid hormone production (low follicular fluid estradiol concentrations and high levels of follicular fluid androgens) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also abnormalities in the dynamics of follicular development. Growth of later (antral) stages of follicles tends to be arrested at 5 to 8 mm in diameter, much smaller than a mature follicle destined to ovulate.",
"   </p>",
"   <p>",
"    Although there is evidence for an abnormal ovarian endocrine environment, it is also possible that there is an intrinsic defect in ovarian folliculogenesis. As an example, in a histological study of ovarian cortical biopsies in women with polycystic ovaries (either anovulatory or ovulatory) and normal controls, the density of small pre-antral follicles was sixfold greater in anovulatory women with PCO compared with normals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/26\">",
"     26",
"    </a>",
"    ]. Within the pre-antral follicular pool, the percentage of early growing (primary) follicles was significantly greater, the percentage of primordial (resting) follicles significantly lower, and there was a trend towards a greater percentage of atretic follicles in the anovulatory PCO patients compared with controls. These findings suggest that although there might be a greater initial pool of follicles in women with PCOS, a higher percentage get recruited and then become atretic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gonadotropin dynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many, but not all, women with PCOS have abnormal gonadotropin secretory dynamics. Most commonly, there is an increase in mean LH levels (",
"    <a class=\"graphic graphic_figure graphicRef52544 \" href=\"UTD.htm?32/4/32845\">",
"     figure 2",
"    </a>",
"    ), and in LH pulse frequency and amplitude when blood is sampled frequently (a minimum of every 10 minutes throughout the day) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The likelihood of finding an elevation in serum LH is dependent on the timing of the sample relative to the last menstrual period, the ovarian activity, the use of oral contraceptive pills, body mass index, and the frequency of LH-sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, the absence of an elevated serum LH level does not exclude the diagnosis of PCOS.",
"   </p>",
"   <p>",
"    The serum concentration of follicle stimulating hormone (FSH) may be normal or low in PCOS, leading to an elevated",
"    <span class=\"nowrap\">",
"     LH/FSH",
"    </span>",
"    ratio compared with normally cycling, early follicular phase young control women. However, neither an elevated serum LH concentration nor an increased",
"    <span class=\"nowrap\">",
"     LH/FSH",
"    </span>",
"    ratio are part of the diagnostic criteria for PCOS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been proposed that prenatal androgenization may program the female fetus to develop LH excess, ovarian and adrenal hyperandrogenism, amenorrhea, and insulin resistance at puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some hyperandrogenic women have mildly elevated serum prolactin levels of uncertain significance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/32\">",
"     32",
"    </a>",
"    ]. The modest elevation in prolactin is thought to result from sensitization by circulating estrogen (estrone) of the pituitary lactotrope to input from the hypothalamus. Levels of prolactin in excess of 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    should prompt further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62513921\">",
"    <span class=\"h2\">",
"     Mood disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that women with PCOS may be more likely to have mood disorders (depression and anxiety), when compared with women of similar BMI without PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. In one cross-sectional study of 117 women with PCOS, 75 (61 percent) had depression that could not be explained by obesity or hyperandrogenic symptoms, as mean BMI and presence of hirsutism or acne was similar in the women with or without depression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/35\">",
"     35",
"    </a>",
"    ]. Women with PCOS also appear to have impaired quality of life, are at risk for eating disorders (binge eating) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/37\">",
"     37",
"    </a>",
"    ], and have higher emotional distress scores when compared with women without PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, the Androgen Excess and PCOS Society suggests screening all women with PCOS for mood disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Metabolic issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Obesity and insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a controlled systematic study has not been performed to determine the exact incidence, most investigators find that at least one-half of women with PCOS are obese. Most women with PCOS are also hyperinsulinemic and insulin resistant, independent of obesity, compared with normal women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In addition, the prevalence of the metabolic syndrome in women with PCOS appears to be increased. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Metabolic syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hyperandrogenemia has a minor effect upon the insulin resistance of PCOS; however, hyperinsulinemia contributes to the hyperandrogenism both directly (through stimulation of androgen biosynthesis in the ovarian theca cell) and indirectly through its suppressive effects on sex hormone binding globulin (SHBG) production by the liver. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=see_link\">",
"     \"Steroid hormone metabolism in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reducing the degree of insulin resistance and hyperinsulinemia with weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/42\">",
"     42",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/43\">",
"     43",
"    </a>",
"    ], or a thiazolidinedione [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/44\">",
"     44",
"    </a>",
"    ], is associated with decreased androgen levels in women with PCOS.",
"   </p>",
"   <p>",
"    We currently do not recommend routine assessment of insulin resistance in a clinical setting since it is not possible to determine the extent to which PCOS contributes to insulin resistance, independent of body weight and adiposity. In addition, the magnitude of insulin resistance does not appear to predict the clinical response to insulin lowering therapies. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the menstrual dysfunction and hyperandrogenic symptoms that characterize PCOS, the risk of type 2 diabetes is increased, particularly in women with a first degree relative with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. As an example, in a study of 122 obese women with PCOS, 45 percent had either impaired glucose tolerance (35 percent) or type 2 diabetes mellitus (10 percent) by age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/45\">",
"     45",
"    </a>",
"    ]. The women with diabetes had a 2.6-fold higher prevalence of first-degree relatives with type 2 diabetes. In a subset of 25 women who underwent repeat oral glucose tolerance testing after a mean of 34 months, 40 percent had a deterioration in glucose tolerance.",
"   </p>",
"   <p>",
"    In a second study of 71 women with PCOS, the annual conversion rate from normal glucose tolerance to impaired glucose tolerance was 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with PCOS and a family history of type 2 diabetes may have an impairment in insulin secretion as well as insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/46,51\">",
"     46,51",
"    </a>",
"    ]. In a study of 33 women with PCOS and 48 of their first-degree relatives who underwent a frequently sampled intravenous glucose tolerance test, there was a significant familial (sibling) correlation for the acute insulin response to intravenous glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/47\">",
"     47",
"    </a>",
"    ]. This suggests that there is a heritable component to beta-cell dysfunction in families of women with PCOS.",
"   </p>",
"   <p>",
"    The frequency of diagnosis of type 2 diabetes may vary with the screening test used. This was illustrated in a report of 254 women with PCOS who underwent both a fasting blood glucose and a 75 g oral glucose tolerance test (OGTT) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/52\">",
"     52",
"    </a>",
"    ]. The American Diabetes Association criteria (based on fasting glucose) underestimated the prevalence of diabetes when compared with the World Health Organization criteria (based on OGTT; 3.2 and 7.5 percent, respectively). Similar findings have been described in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/53\">",
"     53",
"    </a>",
"    ] and in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/54\">",
"     54",
"    </a>",
"    ] with PCOS, where two-hour postchallenge blood glucose levels were abnormal in a greater percentage of subjects than were fasting glucose levels.",
"   </p>",
"   <p>",
"    The evaluation of women with PCOS for glucose intolerance, including guidelines from a number of professional organizations, is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\", section on 'OGTT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The often familial nature of PCOS has led to examination for possible molecular linkages of this disorder to type 2 diabetes. As an example, a unique defect in serine phosphorylation of the insulin receptor that results in decreased activation of the receptor has been identified in about 50 percent of women with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/55\">",
"     55",
"    </a>",
"    ]. Why this occurs is not clear, but serine phosphorylation of CYP17 may also be part of the mechanism of increased adrenal androgen synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, familial PCOS has been linked to an insulin regulatory locus on chromosome 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/57\">",
"     57",
"    </a>",
"    ]. Whether this represents a common genetic defect in PCOS and diabetes or whether it reflects cosegregation of diabetes with PCOS in the tested families remains to be elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of women with PCOS have demonstrated low HDL-cholesterol and high triglyceride concentrations, consistent with their insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/58\">",
"     58",
"    </a>",
"    ], as well as an increase in LDL-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/49,59,60\">",
"     49,59,60",
"    </a>",
"    ]. The approach to metabolic screening of women with PCOS is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one review of 195 obese and non-obese women with PCOS and 65 weight-matched controls, serum LDL-cholesterol was increased in both the obese and non-obese PCOS groups when compared with controls (mean differences of 16 and 32",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.41 and 0.82",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, HDL-cholesterol was modestly but significantly elevated (6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.16",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in the obese women with PCOS, which may provide some degree of protection against cardiovascular disease. Although serum triglyceride concentrations appeared higher in the PCOS patients, it was not a statistically significant difference.",
"   </p>",
"   <p>",
"    In a second study of 398 women with PCOS, the prevalence of abnormal lipid parameters was quite high [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total cholesterol &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.27",
"      <span class=\"nowrap\">",
"       mmol/L):",
"      </span>",
"      35 percent",
"     </li>",
"     <li>",
"      LDL &ge;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.36",
"      <span class=\"nowrap\">",
"       mmol/L):",
"      </span>",
"      31 percent",
"     </li>",
"     <li>",
"      HDL &lt;35",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (.90",
"      <span class=\"nowrap\">",
"       mmol/L):",
"      </span>",
"      15 percent",
"     </li>",
"     <li>",
"      Triglycerides &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.26",
"      <span class=\"nowrap\">",
"       mmol/L):",
"      </span>",
"      16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a case-control study of 11,035 women with PCOS and a group of age-matched controls, those with PCOS were more likely to have dyslipidemia (odds ratio 1.53, 95% CI 1.39-1.68), even after adjusting for BMI and known confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with PCOS are also more likely to have an increase in small dense LDL particles when compared with women of similar body mass index and insulin resistance without PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Small dense LDL is strongly associated with an increased risk of coronary heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the most recent NHANES report (1999 to 2000) the prevalence of the metabolic syndrome (as defined by the National Cholesterol Education",
"    <span class=\"nowrap\">",
"     Program/ATP",
"    </span>",
"    III criteria) in normal women ages 20 to 39 years was approximately 18 to 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/64\">",
"     64",
"    </a>",
"    ]. Using the same diagnostic criteria, the prevalence appears to be much higher in women with PCOS, as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study, 43 percent of PCOS patients had the metabolic syndrome, roughly twofold higher than that of age-matched women in the general population, as reported by the National Health and Nutrition Examination Survey (NHANES III) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, the prevalence of metabolic syndrome in women with PCOS was approximately 47 percent compared with 4 percent in age-matched (but not weight-matched) controls with regular menses and no hirsutism [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the third report, a secondary analysis of 394 women with PCOS participating in a randomized trial (thiazolidinedione versus placebo), the metabolic syndrome was common (33.4 percent of subjects), particularly in those with the highest insulin levels and BMI [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/67\">",
"       67",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for metabolic evaluation of women with PCOS are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280115260\">",
"    <span class=\"h3\">",
"     Nonalcoholic fatty liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), may be increased in women with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In one study, 21 of 70 women (30 percent) with PCOS had elevated serum ALT concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/68\">",
"     68",
"    </a>",
"    ]. In contrast, in a population-based study of over 18,000 adults, an abnormal ALT was seen in only 2 percent of all women, 5 percent of women with type 2 diabetes, and 7 percent of obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    and thiazolidinediones have been studied as a possible therapy for NASH. Data on the efficacy of metformin are conflicting, but biochemical and histologic features of NASH appear to improve with thiazolidinedione therapy, suggesting that this therapy may not necessarily be contraindicated in women with PCOS who also have NASH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=see_link&amp;anchor=H254497165#H254497165\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\", section on 'Thiazolidinediones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Risk for CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of obesity, insulin resistance, impaired glucose tolerance (or type 2 diabetes), and dyslipidemia may predispose women with PCOS to coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/49\">",
"     49",
"    </a>",
"    ]. However, an excess risk of CHD in women with PCOS is suspected, but not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/72\">",
"     72",
"    </a>",
"    ]. The following observations illustrate the range of findings that have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Observational data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on long-term CHD morbidity and mortality in women with PCOS are inconclusive. In one 30-year follow-up study of women who had previously undergone wedge resection surgery (presumably for PCOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], no increased mortality from cardiovascular disease was observed, in spite of an increased prevalence of cardiovascular risk factors, including diabetes.",
"   </p>",
"   <p>",
"    In contrast, in the Nurses' Health Study, a history of menstrual cycle irregularity was associated with an increased risk of nonfatal and fatal coronary heart disease (RR 1.25 and 1.67, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/75\">",
"     75",
"    </a>",
"    ]. This might be explained by a high rate of PCOS with its associated metabolic disturbances in these women, although no clinical or biochemical androgen data were available for confirmation of the PCOS diagnosis. A similar increase in CHD mortality was noted in a second prospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/76\">",
"     76",
"    </a>",
"    ]. However, the magnitude of the effect was attenuated after adjusting for body mass index. In addition, a subgroup analysis from the Women&rsquo;s Ischemia Syndrome Evaluation (WISE) reported that among postmenopausal women with possible ischemia, features of PCOS (history of irregular menses and current hyperandrogenemia), were associated with angiographic evidence of CHD and lower event-free survival after cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/77\">",
"     77",
"    </a>",
"    ]. The severity of the PCOS phenotype may correlate with cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of C-reactive protein (CRP), a biochemical predictor of cardiovascular disease, appear to be commonly elevated in women with PCOS. As an example, in a retrospective analysis of 116 women with PCOS and 96 BMI-matched control women with regular menstrual cycles, serum CRP concentrations were high (&gt;5",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    in 37 and 10 percent of PCOS and control subjects, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Endothelial function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction has been thought to be a contributing factor to the development of atherosclerosis. Data on endothelial function in women with PCOS are conflicting, with some [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/80-83\">",
"     80-83",
"    </a>",
"    ], but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/84\">",
"     84",
"    </a>",
"    ] reporting evidence of endothelial dysfunction in women with PCOS. Insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], high serum concentrations of testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/81\">",
"     81",
"    </a>",
"    ], CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/80\">",
"     80",
"    </a>",
"    ], and total cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/81\">",
"     81",
"    </a>",
"    ], or low serum adinopectin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/83\">",
"     83",
"    </a>",
"    ] were correlated with the observed endothelial dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Functional and imaging studies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiography &mdash; Women with PCOS may have more extensive coronary disease on angiography when compared with normal women. This was illustrated in a report of 143 women younger than age 60 years who were undergoing coronary angiography for assessment of chest pain or valvular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/85\">",
"       85",
"      </a>",
"      ]. Ultrasound appearance of polycystic ovarian morphology was present in 42 percent of the women and was associated with hirsutism, lower levels of HDL-cholesterol, and higher concentrations of free testosterone, triglycerides, and C-peptide, when compared with women with normal-appearing ovaries. The women with polycystic ovaries had more extensive coronary disease on angiography than those with normal ovaries. However, this study did not distinguish between polycystic morphology and true PCOS; thus, the applicability of these findings to women with PCOS is uncertain.",
"     </li>",
"     <li>",
"      Carotid ultrasound &mdash; A tendency toward atherosclerosis was also suggested in an ultrasonographic study of 125 women with PCOS and 142 normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/86\">",
"       86",
"      </a>",
"      ]. Carotid artery intima-media thickness was significantly greater in women with PCOS who were &ge;45 years old than in normal controls. However, the mean intima-media thickness in the PCOS group was still well below that seen in patients with significant carotid artery disease.",
"     </li>",
"     <li>",
"      EBCT &mdash; Electron beam computed tomography (EBCT) is a noninvasive measure of coronary artery calcium (CAC, a marker for atherosclerosis). In a study of 36 premenopausal women (mean age 38 years) with PCOS, the presence of CAC was more common in PCOS patients when compared with a group of age and weight-matched controls (39 versus 21 percent, respectively; odds ratio 2.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/87\">",
"       87",
"      </a>",
"      ]. However, after controlling for BMI, PCOS was no longer a predictor of CAC, suggesting that obese women with or without PCOS are at increased risk of atherosclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second study of 61 women ages 40 to 61 years with PCOS and 85 controls, the prevalence of coronary artery and aortic calcification was higher in the PCOS group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/88\">",
"     88",
"    </a>",
"    ]. Components of the metabolic syndrome (low HDL and insulin resistance) appeared to mediate the association between PCOS and CAC, independently of obesity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a third study of 24 younger women with PCOS (mean age 31 years), coronary artery calcium was detected in eight women (33 percent) compared with 2 of 24 (8 percent) of age- and weight-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/89\">",
"     89",
"    </a>",
"    ]. The increase in risk appeared to be independent of traditional cardiovascular risk factors and markers of inflammation.",
"   </p>",
"   <p>",
"    In summary, an increased risk of cardiovascular disease in women with PCOS is not yet well established. Nevertheless, we recommend that all cardiovascular risk factors be considered for evaluation and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep apnea is common in women with PCOS, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 53 women with PCOS compared with 452 premenopausal controls, obstructive sleep apnea and excessive daytime sleepiness (diagnosed by an overnight sleep study or written questionnaire, respectively) were significantly more common in the PCOS group (OR 30.6 and 9.0, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/90\">",
"       90",
"      </a>",
"      ]. The differences remained significant, even when controlled for BMI. The strongest predictors for sleep apnea were fasting plasma insulin concentrations and glucose-to-insulin ratios.",
"     </li>",
"     <li>",
"      In a second study of 48 women with PCOS, glucose tolerance was directly related to the severity of the sleep-disordered breathing [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third report, 18 obese women with PCOS undergoing overnight polysomnography were more likely than age and weight-matched controls to have obstructive sleep apnea (44 versus 5.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obstructive sleep apnea appears to be an important determinant of insulin resistance, glucose intolerance, and type 2 diabetes in PCOS. This was illustrated in a prospective study of 52 women with PCOS and 21 women without PCOS, of similar age and body mass index who underwent an overnight polysomnogram and a 75 gram oral glucose tolerance test [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/93\">",
"     93",
"    </a>",
"    ]. The following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-nine (56 percent) of women with PCOS had obstructive sleep apnea (OSA) compared with four (19 percent) of controls (odds ratio 7.1).",
"     </li>",
"     <li>",
"      Impaired glucose tolerance was found in 16 of 29 (55 percent) of PCOS women with OSA and only 6 of 23 (26 percent) of those without OSA. In addition, women with PCOS and OSA were more insulin-resistant than those without OSA after controlling for age, body mass index, and ethnicity.",
"     </li>",
"     <li>",
"      The severity of OSA was a highly significant predictor of the fasting concentrations of glucose and insulin as well as the two-hour glucose concentration and HOMA index (an estimate of insulin resistance).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, women with PCOS should be questioned about signs and symptoms of sleep apnea and excessive daytime sleepiness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING PHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethnic, racial, and other cultural factors influence the phenotype of PCOS as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large cohort study of over 11,000 women with PCOS from Kaiser Permanente, black and Hispanic women were more likely and Asians less likely than white women to be obese [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/49\">",
"       49",
"      </a>",
"      ]. After adjusting for BMI, Asians and Hispanic women were more likely to have diabetes; and black women were more likely to have hypertension.",
"     </li>",
"     <li>",
"      In a report of white and Mexican-American women with PCOS, the Mexican-American women were more obese and had higher serum fasting insulin concentrations than white women [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of women with PCOS in the US and Italy, women in the US were more obese, more insulin resistant, and had lower serum HDL concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/95\">",
"       95",
"      </a>",
"      ]. However, total calorie intake and dietary constituents were similar in the two groups, except that women in the US ate more saturated fat. The authors hypothesized that diet alone did not explain the differences in body mass, and that genetic and lifestyle factors likely played a role.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study comparing the phenotype of PCOS in Caucasian women in Boston or Iceland (BMI-matched), serum androstenedione concentrations were higher, and serum LH and testosterone concentrations lower, in the Icelandic compared with Boston women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/17\">",
"     17",
"    </a>",
"    ]. Ovarian volumes and Ferriman-Gallwey scores were also lower in the Icelandic women, but there were no differences in fasting glucose or insulin levels between the two groups.",
"   </p>",
"   <p>",
"    In the same study, the phenotype of PCOS was compared among different ethnic groups in Boston. Serum insulin concentrations and homeostasis model assessment ([HOMA], a measure of insulin resistance) were higher in an African-American subgroup in Boston compared with Caucasian and Asian women. However, these differences could be accounted for by BMI.",
"   </p>",
"   <p>",
"    There were no differences in sex steroid and gonadotropin levels among the different ethnic groups in Boston. These observations suggest that there are differences in the reproductive aspects of the PCOS phenotype in Caucasian Icelandic and Caucasian Boston women. In contrast, differences in insulin dynamics appear to be explained by differences in BMI and not country of origin or ethnic background.",
"   </p>",
"   <p>",
"    Some of the clinical features of PCOS have a familial pattern, including the risk of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/45-48\">",
"     45-48",
"    </a>",
"    ], beta cell dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/47\">",
"     47",
"    </a>",
"    ], dyslipidemia (including high LDL concentrations) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/96,97\">",
"     96,97",
"    </a>",
"    ], menstrual irregularity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/97\">",
"     97",
"    </a>",
"    ], and insulin resistance and hyperandrogenemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/98\">",
"     98",
"    </a>",
"    ]. Although a number of candidate genes have been proposed, none have been verified in large populations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is thought to be one of the most common endocrinopathies in women, affecting between 6.5 and 8 percent of women overall. The syndrome is characterized clinically by oligomenorrhea and hyperandrogenism, as well as the frequent presence of associated risk factors for cardiovascular disease, including obesity, glucose intolerance, dyslipidemia, and obstructive sleep apnea.",
"   </p>",
"   <p>",
"    The clinical manifestations of PCOS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menstrual dysfunction characterized by infrequent or absent menses. However, some women with PCOS have dysfunctional uterine bleeding as a result of their chronic anovulation. The ovulatory dysfunction typically results in infertility and the need for ovulation induction in those who wish to conceive. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Menstrual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperandrogenism, which may include clinical signs (acne, hirsutism, alopecia)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated serum androgen concentrations. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hyperandrogenism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical polycystic appearance of the ovaries on transvaginal ultrasound in the majority of women with irregular menses and hyperandrogenism (using the original ultrasound criteria for polycystic ovaries) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/6/16490/abstract/16\">",
"       16",
"      </a>",
"      ]. However, this ultrasound appearance is non-specific as it may also be seen in normal cycling women. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Ultrasound appearance'",
"      </a>",
"      above.) The ultrasound diagnostic criteria for PCOS are reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"       \"Diagnosis of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal gonadotropin dynamics in most women with PCOS, including high serum LH concentrations, due to an increase in LH pulse frequency and amplitude. The increased LH pulse frequency is likely caused by an increase in GnRH pulse frequency, reflecting disturbance in hypothalamic function. However, serum LH concentrations are affected by body mass index and timing of the blood sample relative to the last menstrual period. Neither an elevated serum LH concentration nor a high LH:FSH ratio is part of the diagnostic criteria for PCOS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"       \"Diagnosis of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A clustering of risk factors for diabetes and cardiovascular disease, including obesity (and insulin resistance), glucose intolerance, and dyslipidemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Obesity and insulin resistance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Dyslipidemia'",
"      </a>",
"      above.) Women with PCOS are at increased risk for type 2 diabetes, but an excess risk of cardiovascular disease has not yet been demonstrated definitively. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Type 2 diabetes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Risk for CHD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other clinical manifestations that may be seen include sleep apnea and nonalcoholic steatohepatitis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Sleep apnea'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H280115260\">",
"       'Nonalcoholic fatty liver disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis, diagnostic criteria for, and treatment of PCOS are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/1\">",
"      Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/2\">",
"      Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/3\">",
"      Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84:4006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/4\">",
"      Asunci&oacute;n M, Calvo RM, San Mill&aacute;n JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/5\">",
"      Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/6\">",
"      Gadducci A, Gargini A, Palla E, et al. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005; 20:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/7\">",
"      Giudice LC. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 2006; 20:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/8\">",
"      Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001; 98:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/9\">",
"      Stein, I, Leventhal, M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/10\">",
"      Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/11\">",
"      Reinehr T, de Sousa G, Roth CL, Andler W. Androgens before and after weight loss in obese children. J Clin Endocrinol Metab 2005; 90:5588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/12\">",
"      McCartney CR, Prendergast KA, Chhabra S, et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab 2006; 91:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/13\">",
"      DeVane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/14\">",
"      Winters SJ, Talbott E, Guzick DS, et al. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000; 73:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/15\">",
"      Poruondo JA, Tejada RF, Benito JA, Bilbao FJ. Laparoscopy, ovarian and endometrial biopsies in secondary amenorrhea. Endoscopy 1982; 14:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/16\">",
"      Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986; 293:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/17\">",
"      Welt CK, Arason G, Gudmundsson JA, et al. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. J Clin Endocrinol Metab 2006; 91:4361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/18\">",
"      Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/19\">",
"      Hague WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol (Oxf) 1990; 33:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/20\">",
"      Koivunen RM, Juutinen J, Vauhkonen I, et al. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 2001; 86:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/21\">",
"      Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries--a common finding in normal women. Lancet 1988; 1:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/22\">",
"      Cela E, Robertson C, Rush K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 2003; 149:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/23\">",
"      Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 2004; 89:4343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/24\">",
"      Murphy MK, Hall JE, Adams JM, et al. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:3878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/25\">",
"      Mason HD, Willis DS, Beard RW, et al. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J Clin Endocrinol Metab 1994; 79:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/26\">",
"      Webber LJ, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003; 362:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/27\">",
"      Waldstreicher J, Santoro NF, Hall JE, et al. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/28\">",
"      Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/29\">",
"      Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994; 79:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/30\">",
"      Zhou R, Bird IM, Dumesic DA, Abbott DH. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:6630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/31\">",
"      Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006; 91:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/32\">",
"      Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril 1984; 41:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/33\">",
"      Thomson RL, Buckley JD, Lim SS, et al. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2010; 94:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/34\">",
"      Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril 2010; 93:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/35\">",
"      Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril 2010; 94:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/36\">",
"      Rassi A, Veras AB, dos Reis M, et al. Prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry 2010; 51:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/37\">",
"      Naess&eacute;n S, Carlstr&ouml;m K, Garoff L, et al. Polycystic ovary syndrome in bulimic women--an evaluation based on the new diagnostic criteria. Gynecol Endocrinol 2006; 22:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/38\">",
"      Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update 2012; 18:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/39\">",
"      Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/40\">",
"      Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/41\">",
"      DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/42\">",
"      Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/43\">",
"      Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/44\">",
"      Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/45\">",
"      Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/46\">",
"      Ehrmann DA, Sturis J, Byrne MM, et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 96:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/47\">",
"      Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001; 86:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/48\">",
"      Ehrmann DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/49\">",
"      Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/50\">",
"      Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/51\">",
"      Goodarzi MO, Erickson S, Port SC, et al. beta-Cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/52\">",
"      Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/53\">",
"      Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ 2007; 176:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/54\">",
"      Palmert MR, Gordon CM, Kartashov AI, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/55\">",
"      Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/56\">",
"      Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995; 92:10619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/57\">",
"      Waterworth DM, Bennett ST, Gharani N, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997; 349:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/58\">",
"      Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/59\">",
"      Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998; 51:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/60\">",
"      Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/61\">",
"      Legro RS, Azziz R, Ehrmann D, et al. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003; 88:5137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/62\">",
"      Berneis K, Rizzo M, Lazzarini V, et al. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/63\">",
"      Phelan N, O'Connor A, Kyaw-Tun T, et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab 2010; 95:3933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/64\">",
"      Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 2004; 27:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/65\">",
"      Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/66\">",
"      Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005; 106:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/67\">",
"      Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/68\">",
"      Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/69\">",
"      Setji TL, Holland ND, Sanders LL, et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/70\">",
"      Cerda C, P&eacute;rez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/71\">",
"      Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 2000; 109:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/72\">",
"      Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002; 186:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/73\">",
"      Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/74\">",
"      Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/75\">",
"      Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/76\">",
"      Wang ET, Cirillo PM, Vittinghoff E, et al. Menstrual irregularity and cardiovascular mortality. J Clin Endocrinol Metab 2011; 96:E114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/77\">",
"      Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/78\">",
"      Jovanovic VP, Carmina E, Lobo RA. Not all women diagnosed with PCOS share the same cardiovascular risk profiles. Fertil Steril 2010; 94:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/79\">",
"      Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/80\">",
"      Tarkun I, Arslan BC, Cant&uuml;rk Z, et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89:5592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/81\">",
"      Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:5088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/82\">",
"      Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86:4666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/83\">",
"      Carmina E, Orio F, Palomba S, et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006; 119:356.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/84\">",
"      Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/85\">",
"      Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997; 126:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/86\">",
"      Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/87\">",
"      Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/88\">",
"      Talbott EO, Zborowski JV, Rager JR, et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:5454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/89\">",
"      Shroff R, Kerchner A, Maifeld M, et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007; 92:4609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/90\">",
"      Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001; 86:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/91\">",
"      Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/92\">",
"      Fogel RB, Malhotra A, Pillar G, et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/93\">",
"      Tasali E, Van Cauter E, Hoffman L, Ehrmann DA. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:3878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/94\">",
"      Kauffman RP, Baker VM, Dimarino P, et al. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol 2002; 187:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/95\">",
"      Carmina E, Legro RS, Stamets K, et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003; 18:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/96\">",
"      Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/97\">",
"      Sam S, Legro RS, Essah PA, et al. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006; 103:7030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/6/16490/abstract/98\">",
"      Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:2031.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7436 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16490=[""].join("\n");
var outline_f16_6_16490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Menstrual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Anovulatory infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ovarian abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ultrasound appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Follicular development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gonadotropin dynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62513921\">",
"      Mood disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Metabolic issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Obesity and insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H280115260\">",
"      - Nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Risk for CHD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Observational data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Endothelial function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Functional and imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      FACTORS AFFECTING PHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7436\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7436|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/25/21918\" title=\"figure 1\">",
"      Androgen levels in PCOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/4/32845\" title=\"figure 2\">",
"      Estrogen levels in PCOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7436|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/5/5203\" title=\"picture 1\">",
"      Hirsutism in PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8298?source=related_link\">",
"      Definition and etiology of recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=related_link\">",
"      Natural history and management of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=related_link\">",
"      Steroid hormone metabolism in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_6_16491="Abdominal pain in AIDS";
var content_f16_6_16491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of abdominal pain syndromes in patients with AIDS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suspect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dull pain, diarrhea, mild nausea, vomiting",
"       </td>",
"       <td>",
"        Infectious enteritis",
"       </td>",
"       <td>",
"        Stool cultures, ova and parasites, sigmoidoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute, severe pain, peritoneal irritation",
"       </td>",
"       <td>",
"        Perforation, infectious peritonitis",
"       </td>",
"       <td>",
"        Abdominal plain films, surgical consultation, ultrasonography, paracentesis; if ascites is present, laparoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right upper quadrant pain, abnormal liver function tests",
"       </td>",
"       <td>",
"        Cholecystitis, cholangitis, hepatic infiltration, cholangiopathy",
"       </td>",
"       <td>",
"        Liver function tests, CT/ultrasound, ERCP, liver biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacute pain, severe nausea and vomiting",
"       </td>",
"       <td>",
"        Obstruction",
"       </td>",
"       <td>",
"        Contrast study, endoscopy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16491=[""].join("\n");
var outline_f16_6_16491=null;
var title_f16_6_16492="Rabies preexposure guide";
var content_f16_6_16492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rabies preexposure prophylaxis guide - United States, 2008",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nature of risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical populations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preexposure recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuous",
"       </td>",
"       <td>",
"        Virus present continuously, often in high concentrations. Specific exposures likely to go unrecognized. Bite, nonbite, or aerosol exposure.",
"       </td>",
"       <td>",
"        Rabies research laboratory workers; rabies biologics production workers.",
"       </td>",
"       <td>",
"        Primary course. Serologic testing every&nbsp;six months; booster vaccination if antibody titer is below acceptable level.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent",
"       </td>",
"       <td>",
"        Exposure usually episodic, with source recognized, but exposure also might be unrecognized. Bite, nonbite, or aerosol exposure.",
"       </td>",
"       <td>",
"        Rabies diagnostic laboratory workers, cavers, veterinarians and staff, and animal-control and wildlife workers in areas where rabies is enzootic. All persons who frequently handle bats.",
"       </td>",
"       <td>",
"        Primary course. Serologic testing every&nbsp;two years; booster vaccination if antibody titer is below acceptable level.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infrequent (greater than population at large)",
"       </td>",
"       <td>",
"        Exposure nearly always episodic with source recognized. Bite or nonbite exposure.",
"       </td>",
"       <td>",
"        Veterinarians and animal-control staff working with terrestrial animals in areas where rabies is uncommon to rare. Veterinary students. Travelers visiting areas where rabies is enzootic and immediate access to appropriate medical care including biologics is limited.",
"       </td>",
"       <td>",
"        Primary course. No serologic testing or booster vaccination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rare (population at large)",
"       </td>",
"       <td>",
"        Exposure always episodic with source recognized. Bite or nonbite exposure.",
"       </td>",
"       <td>",
"        US population at large, including persons in areas where rabies is epizootic.",
"       </td>",
"       <td>",
"        No vaccination necessary.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Minimum acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test. A booster dose should be administered if the titer falls below this level.",
"    </div>",
"    <div class=\"reference\">",
"     Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16492=[""].join("\n");
var outline_f16_6_16492=null;
var title_f16_6_16493="Burns epi mort HIC";
var content_f16_6_16493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Estimated global mortality rates from fire-related burn injuries in 2004: High income countries.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mortality rates are expressed as deaths per 100,000 population. In high income countries (HIC) the mortality rate is the highest in the age group 60 years and older. Mortality is also highest in males from age 15 years and older.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva 2008. Available online at: www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.(Accessed on April 2, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16493=[""].join("\n");
var outline_f16_6_16493=null;
var title_f16_6_16494="Facial features hyper IgE";
var content_f16_6_16494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical facial features in a patient with hyperimmunoglobulin E syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 214px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical facial features in a patient with the hyperimmunoglobulin E syndrome showing broad nose, prominent lower lip, and eczematoid skin with doughy consistency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16494=[""].join("\n");
var outline_f16_6_16494=null;
var title_f16_6_16495="Stage 3 ROP";
var content_f16_6_16495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stage 3 retinopathy of prematurity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In stage 3 ROP, new blood vessels and fibrous tissue grow along the ridge and extend into the vitreous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_6_16495=[""].join("\n");
var outline_f16_6_16495=null;
